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ABSTRACT 
When particles approach a nanoscale size, they exhibit novel properties not seen in 
their bulk counterparts.  Therefore, nanoparticles are widely used in the diagnosis and 
treatment of cancer as imaging, delivery, and therapeutic agents.  However, the main 
challenge is to obtain stable, biocompatible, and tumor-targeting nanomaterials so that 
they preferentially accumulate in cancerous tissue. 
 
Many contemporary therapeutic and imaging approaches to cancer treatment are based 
on specific tumor-targeting biomarkers such as antibody or vitamin binding.  Although 
there are significant successes, the inter- and intra-heterogeneity of tumors, their 
complexity, and their ability to adapt to new conditions often create parts of a tumor 
that do not express enough of the biomarker to be targeted.  On the other hand, 
extracellular tumor acidity, resulting from the metabolic alterations of cancer cells, 
attracts a lot of attention as a novel general tumor biomarker.  pH (Low) Insertion  
Peptides (pHLIP
®
 peptides), discovered in our laboratory, represent a novel class of 
pH-responsive tumor-targeting delivery agents.  
 
The molecular mechanism of a pHLIP
®
 peptide’s action is based on the protonation of 
Asp/Glu residues, which enhances the peptide’s hydrophobicity and promotes the 
membrane-associated folding and insertion of a transmembrane helix.  It was shown 
that pHLIP
®
 peptides have excellent targeting of acidic tumors and specific delivery of 
imaging and therapeutic agents to cancer cells within tumors.  Therefore, it is expected 
that coating nanoparticles with pHLIP
®
 peptides would enhance the stability of 
  
nanomaterials, promote uptake of nanomaterials by cancer cells, and/or facilitate in the 
release of therapeutic and diagnostic molecules to the cytoplasm of cancer cells.   
 
The main goal of this work was the development of novel pHLIP
®
 peptide coated 
nanomaterials for cancer therapy.  More specifically, we introduced and investigated: 
- a family of pHLIP® peptides (along with K-pHLIP, the pH-insensitive 
counterpart to pHLIP
®
); 
- fusogenic, PEGylated liposomes coated with  pHLIP® peptide for the 
delivery of therapeutic molecules; 
- specific delivery to tumors of nanogold® clusters conjugated to the 
pHLIP
®
 peptide; 
- novel pHLIP® and PEG coated spherical and spiked gold nanoparticles  
 
A variety of rationally designed pHLIP
®
 variants were characterized.  It was shown 
how tuning the biophysical properties of the peptide–lipid bilayer interactions alter: i) 
tumor-targeting, ii) distribution in organs, and iii) blood clearance.  Also presented, is 
the current understanding of the main principles of pHLIP
®
 design.  All pHLIP
®
 
coated nanomaterials in this work that have been administered to cancerous cells have 
shown a pH-dependent interaction in vitro and/or in vivo.  
 
A novel type of pH-sensitive, “fusogenic” pHLIP® liposomes was developed.  These 
pHLIP

 liposomes displayed enhanced membrane fusion in a pH-dependent fashion 
  
that leads to the increase of cellular uptake and payload release in vitro, highlighting 
their future use as drug delivery agents.   
 
The uptake and retention of nanogold
®
 clusters in acidic tumors was significantly 
enhanced by conjugating the clusters with pHLIP
®
 peptides, further supporting the 
significance of pHLIP

 peptide’s presence in nanomaterial coating for tumor-
targeting.  Furthermore, K-pHLIP (the pH-insensitive version of pHLIP
®
) failed to 
target tumors in vivo.   
 
A novel approach for the synthesis of pHLIP
®
 and PEG coated spherical gold 
nanoparticles was introduced.  These nanoparticles showed enhanced stability in 
solution and homogeneous tumor uptake with no staining of the surrounding muscle 
tissue.  Potentially, they could be used for the enhancement of x-ray radiation.  Novel 
spiked gold nanoparticles coated with pHLIP
®
 and PEG were also created.  Spiked 
particles exhibited plasmonic resonance in the near infrared region.  The particle 
solutions were heated by an 805 nm laser, thereby demonstrating a potential 
application in photothermal therapy.   
 
We believe that pHLIP
®
 coated nanomaterials will find a great range of applications in 
the treatment of cancerous tumors. 
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PREFACE 
This dissertation is written in the “Manuscript Format” using the Thesis/Dissertation 
template of University of Rhode Island.  There are four manuscripts, each organized 
into a chapter.  The figures and tables of each manuscript are listed under the 
corresponding chapter in the list of figures and tables. 
 
The results of our studies presented here in the first three chapters were published in 
three papers: 
1. D. Weerakkody, A. Moshnikova, M. S. Thakur, V. Moshnikova, J. Daniels, D. 
M. Engelman, O. A. Andreev, Y. K. Reshetnyak, “Family of pH (Low) insertion 
peptides for tumor targeting,” Proced. Natl. Acad. Sci U.S.A., 110, 5834-5839 
(2013). 
2. L. Yao, J. Daniels, D. Wijesinghe, O. A. Andreev, Y. K. Reshetnyak, “pHLIP®-
mediated delivery of PEGylated liposomes to cancer cells,” Journal of 
Controlled Release, 167, 228-237, (2013). 
3. L. Yao,  J. Daniels,  A. Moshnikova, S. Kuznetsov, A. Ahmed, D. M. 
Engelman, Y. K. Reshetnyak, O. A. Andreev, “pHLIP peptide targets nanogold 
particles to tumors,” Proced. Natl. Acad. Sci U.S.A., 110, 465-470, (2013).  
 
The final chapter is composed of research in preparation for publication: 
4. J.L. Daniels, T.M. Crawford, O.A. Andreev, Y.K. Reshetnyak, “pHLIP® Coated 
Gold Nanoparticles,” in preparation.  
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ABSTRACT 
Cancer is a complex disease with a range of genetic and biochemical markers within 
and among tumors, but a general tumor characteristic is extracellular acidity, which is 
associated with tumor growth and development. Acidosis could be a universal marker 
for cancer imaging and the delivery of therapeutic molecules, but its promise as a 
cancer biomarker has not been fully realized in the clinic. We have discovered a 
unique approach for the targeting of acidic tissue using the pH-sensitive folding and 
transmembrane insertion of pH (Low) Insertion Peptide (pHLIP). The essence of the 
molecular mechanism has been elucidated, but the principles of design need to be 
understood for optimal clinical applications. Here, we report on a library of 16 
rationally designed pHLIP variants. We show how the tuning of the biophysical 
properties of peptide–lipid bilayer interactions alters tumor targeting, distribution in 
organs, and blood clearance. Lead compounds for PET/single photon emission 
computed tomography and fluorescence imaging/MRI were identified, and targeting 
specificity was shown by use of noninserting variants. Finally, we present our current 
understanding of the main principles of pHLIP design. 
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INTRODUCTION 
The promise of exploiting tumor acidosis as a cancer biomarker has not been fully 
realized in clinical practice, even though the acidity has been a known property since 
the work of Otto Warburg nearly a century ago. The problem has been to find a 
practical way to target acidity. While studying membrane protein folding, we 
discovered a peptide (pH (Low) Insertion Peptide called pHLIP

) that reversibly folds 
and inserts across membranes in response to pH changes, and this discovery has led to 
a novel way to target acidic tissue. Our biophysical studies have revealed the 
molecular mechanism of pHLIP action, which is based on the increase of 
hydrophobicity of carboxyl groups when they become protonated under mildly acidic 
conditions, leading to peptide insertion into a membrane (1-4). We have shown that 
pHLIP can target acidic tissue and selectively translocate polar, cell-impermeable 
molecules across cell membranes in response to low extracellular pH (1, 5-10). As 
noted in the Molecular Imaging and Contrast Agent Database (MICAD) at NCBI, a 
pHLIP labeled with a fluorescent dye or a PET-agent (
64
Cu-DOTA) is a marker for in 
vivo acidity (1, 5, 6), and it has recently been reported that a pHLIP peptide labeled 
with SPECT (
99
Tc) probe targets acidic tumors (7), as well as PET (
18
F) probe 
(Daumar et al., in press in Bioconjugate Chemistry). All prior studies in vivo were 
carried out with the WT-pHLIP sequence and showed that a good contrast and tumor 
to blood ratio can be achieved only more than 24 hours after pHLIP injection, when it 
has accumulated in the tumor and largely cleared from the blood (6, 7). However, for 
the use of pHLIP-based radioactive imaging agents in the clinic, a more rapid 
background signal reduction is absolutely essential. To address this important need, to 
4 
 
tune tumor targeting properties, and to broaden our understanding of the molecular 
mechanism of pHLIP action, we designed a set of 16 pHLIP variants based on 
chemical and physical principles. Comprehensive biophysical studies performed with 
non-labeled peptides were correlated with investigations of tumor targeting and organ 
distributions of fluorescent versions of the pHLIP variants. As a result, a set of design 
criteria has been established, and pHLIP candidates for imaging and therapeutic 
applications, including lead compounds for PET/SPECT and fluorescence/MR 
imaging, have been identified. 
 
MATERIALS AND METHODS 
Conjugation of pHLIP variants with fluorescent dyes 
pHLIP variants were prepared by solid-phase peptide synthesis using Fmoc (9-
fluorenylmethyloxycarbonyl) chemistry and purified by reverse phase chromatography 
at the W.M. Keck Foundation Biotechnology Resource Laboratory at Yale. For cell 
and in vivo stides variants were conjugated with AlexaFluor

750-C5-maleimide, 
Tetramethylrhodamine-5-maleimide, single isomer or BODIPY

-TMR-C5-maleimide 
(Invitrogen). The details of peptides conjugation could be found in Supplementary 
data. 
Steady-state fluorescence and circular dichroism measurements  
Peptide intrinsic fluorescence and circular dichroism (CD) measurements were carried 
out on a PC1 ISS spectrofluorometer (ISS, Inc.) and a MOS-450 spectrometer 
(Biologic, Inc.), respectively, under temperature control at 25
o
C. Peptide fluorescence 
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spectra were recorded with the spectral widths of excitation and emission slits set at 4 
and 2 nm, respectively, using excitation wavelengths of 295 or 280 nm. The 
concentrations of the peptides and POPC liposomes were 7 µM and 1.5 mM, 
respectively. The method of liposome preparation and oriented circular dichroism 
measurments could be found in Supplementary data. 
 
Titration experiments 
Samples containing 5 µM of peptides and varying concentrations of lipids were 
prepared using an electronic repeater pipette (Eppendorf). Different pHs were used for 
peptides with different pKas of insertion; the pH of the solution was one pH unit 
below the apparent pK value for each peptide. The samples at high and low pHs were 
allowed to equilibrate at 4C overnight or 2 hours, respectively, before the 
measurements. The peptide intrinsic fluorescence spectra were measured using 280 
nm excitation at 25C with the emission polarizer set at 90 to reduce the 
contribution of scattered light. A series of POPC blanks with the same 
concentrations of lipids at pH8 were measured with the same instrument settings and 
were subtracted from the corresponding fluorescence spectra of peptides in the 
presence of POPC. The areas under the emission spectra were calculated and the 
values were normalized to the first point (the emission of the peptide in the absence of 
POPC). The titration data were fitted by the peptide-membrane partition model to 
calculate the mole-fraction partition coefficient, K 
𝐹 = 𝐹0 + ∆𝐹
𝐾 ∙ 𝐶𝑙𝑖𝑝
𝑊 + 𝐾 ∙ 𝐶𝑙𝑖𝑝
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where F
0
 and F
 
are the fluorescence intensity at the beginning and fluorescence 
increase as a result of the titration (in our case F
0
 is 1), C
lipids 
is the concentration of 
lipids; W is the molar concentration of water (55.3 M). Nonlinear least squares curve 
fitting procedures using Levenberg-Marquardt algorithm were implemented in Origin 
8.5.0 SR1. The Gibbs free energy (G) was calculated according to the equation: 
∆𝐺 = −𝑅𝑇 ∙ 𝑙𝑛(𝐾) 
Where R is the gas constant and T is the temperature in Kelvin.  
 
pH-dependence 
The pH-dependent partitioning of the peptides into lipid bilayers was investigated by 
the shift of the position of the peptide intrinsic fluorescence spectral maximum for the 
pHLIP variants induced by a drop of pH from 8 to 3 by addition of HCl in the 
presence of POPC liposomes. 3 μM of the peptide was incubated overnight with 2 mM 
of 100 nm POPC liposomes, and the pH was decreased by the addition of aliquots of 
4, 2, 1 and 0.1 M HCl. The resulting pHs were measured using a micro-electrode 
probe (Thermo Electron Corporation, Orion Ross Micro pH electrode). Fluorescence 
spectra were recorded at each pH value. The spectra were analyzed by decomposition 
algorithms using an on-line PFAST toolkit (Protein Fluorescence And Structural 
Toolkit: http://pfast.phys.uri.edu/) to obtain spectral maxima (max). Finally, the 
positions of the fluorescence spectral maxima (max) of the single component solutions 
were plotted versus pH and the Henderson–Hasselbalch equation was used to fit the 
data: 
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𝜆𝑚𝑎𝑥 = 𝜆𝑚𝑎𝑥
2 +
(𝜆𝑚𝑎𝑥
1 − 𝜆𝑚𝑎𝑥
2 )
1 + 10𝑛∙(𝑝𝐻−𝑝𝐾𝑎)
 
where 1max and 
2
max are the beginning and end of the transition, n is the cooperativity 
parameter, and the pKa is the midpoint of the transition. The details of assumptions 
made for the analysis of pH-dependence data could be found in Supplementary.  
 
Stopped–flow fluorescence measurements  
Stopped–flow fluorescence measurements were carried out on a SFM-300 mixing 
apparatus connected to a MOS-450 spectrometer (Biologic, Inc.) under temperature 
control. All solutions were degassed for several minutes under vacuum before loading 
into the syringes to minimize air bubbles. pHLIP variants (7 μM) were pre-incubated 
with POPC (1.5 mM) at pH 8.0 to reach binding equilibrium, and insertion was 
induced by fast mixing (5 ms dead time) of equal volumes of pHLIP-POPC variants at 
pH 8.0 and appropriately diluted HCl, to obtain a drop of pH from 8 to the desired 
value. Each kinetic curve was recorded several times (~10) and then averaged, 
excluding the first 2-3 shots.  
 
Cell lines  
Human cervix adenocarcinoma (HeLa) and human lung carcinoma (A549) cells were 
acquired from the American Type Culture Collection. Human lung carcinoma and 
human cervix adenocarcinoma with stable expression of green fluorescent protein 
(GFP), A549-GFP and HeLa-GFP, respectively, were acquired from Cell Biolabs Inc. 
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Cells were authenticated, stored according to supplier’s instructions, and used within 3 
months after frozen aliquot resuscitations. Cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 
μg/mL of ciprofloxacin in a humidified atmosphere of 5% CO2 and 95% air at 
37°C. The pH5.9 medium was prepared by mixing 13.3 g of dry DMEM in 1 L of 
deionized water. Human cervical epithelial cells (HCvEpC), human mammary 
epithelial cells (HMEpC) and human bronchial epithelial cells (HBEpC) were 
acquired from Cell Applications Inc. Cells were authenticated, stored according to 
supplier’s instructions, and used within 2 months. HCvEpC, HMEpC and HBEpC cells 
were cultured in cervical, mammary and bronchial epithelial cell growth medium, 
respectively, provided by Cell Applications Inc.  
  
Fluorescence Microscopy 
HeLa-GFP and A549-GFP cells were grown in 35-mm dishes with 14-mm glass-
bottom windows coated with poly-d-lysine or collagen. Cells were washed with 
DMEM not containing FBS, pH 5.9 or 7.4 and then incubated with 2 μM of Rho- or 
BODIPY-labeled Var-3, K-Var3, Var7 or K-Var7 peptides at pH 5.9 or pH 7.4. After 
30 minutes of incubation, cells were washed 4-5 times. Fluorescent images were 
acquired with a Retiga CCD camera (Qimaging, Burnaby, BC, Canada) mounted to an 
inverted Olympus IX71 microscope (Olympus America, Inc., Center Valley, PA). 
The details of cellular uptake quantification could be found in Supplementary data. 
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Cytotoxicity Assay  
HeLa, A549, HCvEpC, HMEpC or HMEpC cells were loaded in the wells of 96-well 
plates (~5,000 cells per well) and incubated overnight. The increasing amounts of 
pHLIP variants (1, 2, 4 and 8 μM) were added to HCvEpC, HMEpC or HMEpC cells, 
or growth medium was replaced with the medium without FBS containing increasing 
amounts of pHLIP in case and after 3 hours of incubation an equal volume of the 
medium containing 20% of FBS was added in case of Hela and A549 cells. After 24, 
48 and 72 hours of incubation, a colorimetric reagent (CellTiter 96 AQueous One 
Solution Assay, Promega) was added for 1 hour followed by measuring absorbance at 
490 nm to assess cell viability. All samples were prepared in triplicate. None of the 
tested pHLIP variants showed any cytotoxic effect.   
 
Animal studies 
Athymic female nude mice ranging in age from 4 to 6 weeks and weighing from 15 to 
18 g were obtained from Harlan Laboratories (Indianapolis, IN). In total, 266 mice 
were used in the experiments, and the number of mice used to study each pHLIP 
variant can be found in Tables S2-S5 of the Supplementary Data. Mouse tumors were 
established by subcutaneous injection of HeLa-GFP or A549-GFP cells (10
6
 cells/0.1 
ml/flank) in the right flank of each mouse. When tumors reached 5-6 mm in diameter, 
tail vein injections of 100 μl of Alexa750-pHLIPs (40 μM) were performed. Animals 
were imaged at 4 and 24 hours post-injection on a FX Kodak in-vivo image station 
under gas anesthesia with supplemental heat provided to maintain core body 
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temperature. Animals were euthanized at 4 or 24 hours, and necropsy was performed 
immediately after euthanization. Tumors and major organs were collected for further 
imaging. The tumor/organ ratio was calculated according to the equation: 
𝑇𝑢𝑚𝑜𝑟
𝑂𝑟𝑔𝑎𝑛
=
𝐹𝑡𝑢𝑚𝑜𝑟−𝐹𝑏𝑎𝑐𝑘𝑔
𝐹𝑜𝑟𝑔𝑎𝑛−𝐹𝑏𝑎𝑐𝑘𝑔
  
where Ftumor , Forgan and Fbackg are the mean fluorescence intensities of tumor, organ, 
and background signal, respectively. The contrast-to-noise ratio (CNR) was calculated 
according to the equation: 
𝐶𝑁𝑅 =
𝐹𝑡𝑢𝑚𝑜𝑟 − 𝐹𝑏𝑎𝑐𝑘𝑔
𝑆𝐷𝑏𝑎𝑐𝑘𝑔
 
where SDbackg is the standard deviation of the background signal. Fluorescence 
intensity was obtained from image analysis using Kodak software. Statistical analysis 
of the data was performed using the “Statistica 5.0” package. The p-level was 
computed based on the two-tailed test. All animal studies were conducted according to 
an approved University of Rhode Island animal protocol (AN07-01-015), in 
compliance with the principles and procedures outlined in the NIH Guide for the Care 
and Use of Animals. 
 
RESULTS 
Design of pHLIP variants 
We have reported the basic molecular mechanism of the interaction of WT-pHLIP 
with lipid bilayers (1, 3, 11). In these studies we found three states of the peptide: 
State I, in solution as an unstructured monomer at neutral pH when no lipid membrane 
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is present; State II, bound at the surface of a lipid bilayer as a largely unstructured 
monomer at neutral pH, and State III, inserted across the bilayer as a monomeric helix 
at acidic pH. To broaden our understanding of the main principles of pHLIP peptide 
interactions with membranes and to select the best sequences for clinical use, we 
employed our knowledge and designed 16 variants of the WT-pHLIP (Var0) 
sequence: 
Var0-WT  ACEQNPIY  WARYADWLFTTPLLLLDLALLV DADEGT  
Var1-2D1D ACEDQNPY  WARYADWLFTTPLLLLDLALLV DG  
Var2-2D1D ACEDQNPY  WRAYADLFTPLTLLDLLALW DG   
Var3-3D  ACDDQNP   WRAYLDLLFPTDTLLLDLLW    
Var4-3E  ACEEQNP   WRAYLELLFPTETLLLELLW    
Var5-3Da  ACDDQNP   WARYLDWLFPTDTLLLDL     
Var6-3Db  CDNNNP    WRAYLDLLFPTDTLLLDW     
Var7-3Ea  ACEEQNP   WARYLEWLFPTETLLLEL     
Var8-3Eb  CEEQQP    WAQYLELLFPTETLLLEW     
Var9-3Ec  CEEQQP    WRAYLELLFPTETLLLEW     
Var10-2D  ACEDQNP   WARYADWLFPTTLLLLD     
Var11-2E  ACEEQNP   WARYAEWLFPTTLLLLE     
Var12-1D  ACEDQNP   WARYADLLFPTTLAW     
Var13-1E  ACEEQNP   WARYAELLFPTTLAW     
Var14-Rev Ac-TEDAD  VLLALDLLLLPTTFLWDAYRAW YPNQECA-Am 
Var15-2N  CDDDDDNPNY WARYANWLFTTPLLLLNGALLV EAEET  
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Var16-2P  CDDDDDNPNY WARYAPWLFTTPLLLLPGALLV EAEET 
  
Biophysical studies 
First, we studied the interaction of the pHLIP variants with lipid bilayers, employing 
the fluorescence and CD spectroscopic techniques previously used (3). The intrinsic 
tryptophan fluorescence and CD spectra of non-labeled variants measured in solution 
at pH8 in the absence and presence of POPC liposomes and in the presence of 
liposomes at low pH (pH 4-5) indicate that each peptide interacts with a lipid bilayer 
in a pH-dependent manner and that the peptides form transmembrane helices in state 
III (Supplementary Table S1 and Figure S1).  
 
The partitioning of pHLIP variants into bilayers at pHs 8 and 4-5 was assessed in 
titration experiments by measuring changes of intrinsic peptide fluorescence (Figure 
1). On average, the partitioning of the variants into the membrane at low pH is about 
50 fold higher than at high pH. As expected, the truncated variants Var5-13 have 
lower affinities for the membrane at neutral pH compared to WT and other variants, 
since a number of hydrophobic residues were removed from the sequences. In general, 
variants with Glu residues have slightly higher affinities compared to the same 
variants with Asp (since Glu is more hydrophobic due to the additional methylene 
group). The highest affinity was observed for Var15, which forms a helical structure at 
neutral pH. At low pH, the lowest affinity for the lipid bilayer was observed for the 
most truncated versions Var10-13 and variants (Var15 and 16) with no protonatable 
residues in the TM, which reflects the reduced stability of the TM helix. The numbers 
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below are the differences between the Gibbs free energies of the interactions of 
variants with the membrane at low and high pHs (in kcal/mol): G = GpH4  GpH8 
Var1 Var2 Var3 Var4 Var5 Var6 Var7 Var8 Var9 Var10 Var11 Var12  
2.17 0.28 2.23 1.72 2.31 1.93 2.39 2.19 2.07 1.79  1.94  1.95   
Var13 Var14 Var15 Var16 
1.15  1.78  0.82  1.47 
 
The above numbers reflect both the differences in binding affinities, and to some 
degree, the strength of the helical structure formation in the membrane. The largest 
differences are observed for Var3, Var5, and Var7. The smallest differences are found 
for Var2 and Var15 due to the strong interactions of these peptides with the bilayer in 
state II at pH8. 
 
The pKa of peptide insertion is determined by the pKa of protonation of Asp/Glu 
residues in the TM and at the inserting end of the peptide. As charged carboxyl groups 
located at the transition zone between the aqueous and hydrophobic environments sink 
more deeply into the bilayer, the pKa is progressively raised by the reduced dielectric 
constant, and the pKa of Asp/Glu residues increases. Thus, all truncated variants 
(Var5-13), which demonstrated weaker interactions with lipid bilayer surfaces at 
neutral and high pHs, would have lower pKa’s of insertion. The pKa of pHLIP variant 
insertion was measured by following the shift of the position of the intrinsic peptide 
emission maximum as the pH is changed from 8 to 2 (Figure 2). As expected, the shift 
of pKa to lower pHs correlates with the truncation of the pHLIP sequence. Thus, the 
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pKa of Var10, with a single Asp residue in its TM, is the lowest (pKa=4.5). All 
variants containing Glu residues (Var7-9, 11, 13) have higher pKa values compared to 
the related sequences with Asp residues (Var5-6, 10, 12), again as expected if the 
increased hydrophobicity of the Glu causes a deeper association with the bilayer, 
lowering the dielectric and raising the pK. 
 
To this point, we have considered the equilibrium energies of progressive binding and 
insertion events, but it is also important to note that sequence variation will alter the 
kinetics of insertion. The barrier for insertion includes the resistance to the passage of 
the inserting terminal end of the peptide from the aqueous compartment outside to the 
aqueous compartment inside a cell or liposome. We have found in recent work that the 
kinetics of insertion correlates with the number of protonatable groups at the inserting 
end or the presence of polar cargo (12). The characteristic membrane insertion time 
for WT-pHLIP is about 30 sec, and slightly faster kinetics were observed for Var14, 
which is the reverse sequence of WT. Var14 has the same number of protonatable 
residues at its N-terminus as WT has at its C terminus, except for the free C-terminus 
itself. The data are consistent with the view that the acetylated N-terminus of Var14 
inserts across the bilayer and the amidated C-terminus stays outside, reversing the 
direction of insertion. The characteristic time of Var1-2 insertion, which has fewer 
protonatable residues at its C-terminus than WT, was about 1-2 sec, which correlates 
well with our recent findings (12). Further truncation of the peptide inserting end, 
which reduces the number of protonatable residues, resulted in faster peptide insertion, 
completed within the first 30-100 msec for Var3-13. Var15-16 have no protonatable 
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residues in the TM, while they have the same number of Asp/Glu as WT at the 
inserting end, and as a result the time of insertion was reduced to 10-11 sec relative to 
WT. The kinetics data are shown in Figure 3. 
 
Tumor targeting and distribution of Alexa750-pHLIPs in organs 
We used a mouse xenograft model to assess the tumor targeting and organ distribution 
of the pHLIP variants. Tumors were created by subcutaneous injection of HeLa-GFP 
cancer cells in the right flanks of each mouse, and were grown to about 5 mm in 
diameter. To perform biodistribution studies, pHLIP variants were conjugated with 
Alexa750. We demonstrated that the kinetics of insertion of Alexa750-WT-pHLIP into 
lipid bilayers is similar to the kinetics of insertion of non-labeled peptide 
(Supplementary Figure S2). Fluorescently labeled pHLIPs were given as single 
intravenous injections, and the major organs and tumors were collected at 4 and 24 
hours after fluorescent pHLIP administration. The GFP and NIR signals were 
monitored in tumors and organs after sacrificing the mice. The mean intensities of 
NIR fluorescence normalized to the signal in kidneys at 4 hours are shown on 
Supplementary Figure S3. The mean intensities of NIR fluorescence of all organs and 
the number of mice used in the study for each variant are given in Supplementary 
Table S2 and Table S3. 
 
The pHLIP variants that show higher affinities for membranes at high pH have higher 
short-term liver uptake (Var 1, 2, 4, 14-16), however the liver is cleared at 24 h except 
for Var1. Var3 has high tumor targeting compared to kidney and compared to other 
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pHLIPs as well. Whole-body (data not shown) and organ imaging confirmed that the 
truncated variants Var5-13 have much faster blood clearance than WT, and at 4 hours 
the signal has accumulated in the tumor, while being washed out of the organs. Tumor 
targeting was minimal for the shortest pHLIP variants Var12-13. The tumor/muscle, 
tumor/kidney and tumor/liver ratios are given in Figure 4 for all pHLIP variants 
calculated at 4 and 24 h after injection. Variants 0, 3-4, 14-16 have the highest 
tumor/muscle ratio at 24 hours. The same pHLIP variants have the highest 
tumor/kidney ratios, while only Var3 shows significantly less accumulation in the 
liver. Among the truncated pHLIP variants, Var7 demonstrates the highest tumor 
targeting.  
 
This body of work allows us to propose different pHLIP variants for different 
applications. We have selected Var3 and Var7 as the best candidates for future studies 
for fluorescence/MRI and SPECT/PET imaging, respectively, guided by the fact that 
the imaging time window for the stable fluorescence and MRI agents can be much 
wider than for the short half-life SPECT and PET agents. Var3 had the highest 
tumor/organ ratios, especially at 24 hours after construct administration. Var7 had a 
lower tumor/organ ratio, but showed much faster blood clearance. The cytotoxicity of 
the selected pHLIP variants was evaluated on human cervix adenocarcinoma cells 
(HeLa), human lung carcinoma (A549) cells as well as human cervical (HCvEpC), 
mammary (HMEpC) and bronchial (HBEpC) epithelial cells. Peptides at 
concentrations of up to 8 μM were evaluated up to 72 hours incubation with cells, and 
no toxicity was observed.  
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pH-insensitive K-pHLIPs 
As a control, we have previously used K-pHLIP-WT, where the two key Asp residues 
in the TM part of the peptide were replaced by Lys residues (1). K-pHLIP cannot 
interact with a membrane in a pH-dependent manner over the range of neutral and low 
pHs we are studying, and therefore should not target acidic tumors. Because of the 
potential clinical applications of Var3 and Var7 we synthesized and tested K-versions 
of each: 
K-Var3 ACDDQNP WRAYLKLLFPTKTLLLKLLW     
K-Var7 ACEEQNP WARYLKWLFPTKTLLLKL     
 
Each of these peptides failed to interact with lipid bilayers in a pH-dependent fashion 
(Figure 5a-b). No shift in the position of the peptide fluorescence maximum was seen 
for either of the K-pHLIPs in the presence of lipid as a result of pH decrease, and the 
CD spectra do not change and do not exhibit the minimuma at 208 and 225 nm that are 
characteristic signals reporting alpha-helical conformations. The CD spectra reveal a 
negative band at 234 nm and a positive band at 221 nm, suggestive of an exciton split 
doublet (3, 13) possibly arising from peptide aggregation. 
 
Var3 and Var7, as well as K-Var3 and K-Var7 were conjugated with two different 
fluorescent dyes: zwitterionic, tetramethylrhodamine (Rho), and non-charged, 
BODIPY to ensure that distribution and localization of fluorescent peptides is 
independent of the choice of dye. The fluorescence images demonstrating cellular 
uptake of Rho- and BODIPY-labeled Var3, Var7, K-Var3, and K-Var7 are shown in 
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Figure 5c-d and Supplementary Figure S4, respectively. The fluorescence signal of 
cells treated with fluorescent Var3 and Var7 at pH7.4 was weaker compared to cells 
treated with peptides at pH5.9. The cellular uptake of Var3 was 1.12 times higher at 
low pH compared to neutral pH, and the uptake of Var7 was 1.34 times higher at low 
pH. Our biophysical data show that the affinity of Var3 for a membrane at pH8 is 
higher than the affinity of Var7 at the same pH, therefore we see slightly higher 
cellular uptake of Var3 at pH7.4 compare to Var7 and a less pronounced difference in 
cellular uptake between neutral and low pHs for Var3. For the cases of K-Var3 and K-
Var7, the fluorescence signal was very similar when cells were treated at either high or 
low pHs; moreover, the fluorescence signal at pH7.4 was slightly higher than at 
pH5.9. Also, the distributions of fluorescent signals for D- and E-variants and K-
variants were different. K-Var3 and K-Var7 were distributed as cytoplasmic dots. In 
contrast to pHLIP variants, K-pHLIPs are positively charged and partially aggregated, 
and, most probably, might be taken up by endocytosis and trapped in endosomes in a 
pH-independent manner, while cellular uptake of Var3 and Var7 is pH-dependent.  
Biodistribution and tumor targeting of Alexa750-K-pHLIPs were also investigated 
using xenograft models in mice. In contrast to Var3 and Var7, K-pHLIPs did not show 
significant tumor targeting (Figure 5e-f and Supplementary Table S4). To demonstrate 
that tumor targeting by Var3 and Var7 and the lack of tumor targeting by K-Var3 and 
K-Var7 is independent of choice of tumor model and imaging fluorescent probe, we 
used BODYPI labeled Var3, Var7, K-var3 and K-Var7, which were tested on tumors 
created by subcutaneous injection of A549-GFP human lung carcinoma cells. The 
organs were collected at 4 hours and analyzed (Supplementary Table S5). The tumor 
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to muscle ratio at 4 hours for Var3 and Var7 labeled with BODIPY and Alexa750 was 
6.00.9, while for K-Var3 and K-Var7 it was 2.60.3 (Figure 5g). Thus, the 
replacement of the Asp/Glu residues by Lys in the TMs of Var3 and Var7 leads to the 
loss of both pH-dependent interactions with membranes and targeting of acidic 
tumors, supporting a central role for the carboxyl groups in targeting. 
 
DISCUSSION 
Rapid cell growth and an inadequate blood supply produce hypoxic conditions that 
cause a partial use of glycolysis in tumor cells, resulting in acidification of the cytosol, 
to which the cell adjusts by pumping protons into the external environment. But, 
hypoxia and low blood supply are not the only mechanisms responsible for the 
development of an acidic environment within solid tumors (14). Malignant cancers 
have an elevated glucose uptake even under normal oxygen conditions, overwhelming 
the mitochondrial capacity and using glycolysis for the overflow. This condition is 
known as “aerobic glycolysis” or the Warburg effect (15). Cells exhibiting a Warburg 
effect catabolize glucose at a high rate (16, 17), and the use of glycolysis results in a 
much higher level of production of H
+
 and lactic acid, which are pumped across cell 
plasma membranes into the extracellular space, where they accumulate in poorly 
perfused regions (18-20). In addition to the lactic acid-output, intracellular titration of 
acid with bicarbonate and the engagement of the pentose phosphate shunt releases 
CO2 from tumor cells. Expression of carbonic anhydrase 9 and 12 on the tumor cell 
surface catalyzes the extracellular trapping of acid by hydrating cell-generated CO2 
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into HCO3
−
 and H
+
 (21, 22). These mechanisms combine to create an acidic 
extracellular milieu favoring tumor growth, invasion, and development. 
 
The pHLIP peptides can exploit tumor acidity as a useful biomarker. Based on the 
results of our previous and current investigations, design principles can be formulated 
to set directions for different clinical uses:  
i) all pHLIP peptides have a membrane-binding sequence, which contains a 
number of hydrophobic residues essential for membrane targeting;  
ii) a pHLIP is stable across a lipid bilayer at low pH; 
iii) to achieve pH-dependent targeting, at least one protonatable group (Asp or 
Glu, or any other) needs to be in the sequence; 
iv) in addition to the membrane-binding sequence, a pHLIP peptide may 
contain a membrane inserting sequence (the C-terminus for most 
investigated pHLIPs or the acetylated N-terminus of the reverse pHLIP 
sequence), which crosses the lipid bilayer and emerges in the cytoplasm. 
The protonatable residues could be only in the inserting sequence or in 
both the TM and inserting parts of the peptide;  
v) the number of protonatable residues increases the cooperativity of the 
transition, narrowing the pH range over which insertion occurs; 
vi) the non-inserting flanking sequence may be used for modulation of peptide 
solubility, for example by adding polar and negatively charged residues at 
the non-inserting end (all pHLIP peptides are soluble in aqueous solution at 
neutral and high pHs).  
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The list of the major biophysical properties that affect tumor targeting by pHLIP 
peptides could be found in Supplement data.  
 
Based on the studies reported here, and motivated by potential clinical applications, 
we selected two pHLIP variants for further development (in addition to WT-pHLIP):  
Var3 and Var7. For each of these variants we tested versions with the TM carboxyl 
groups replaced by amino groups (D to K and E to K), and showed that the K-peptides 
lose their abilities to interact with membranes in a pH-dependent manner and to target 
tumors in vivo. Var3 demonstrates high tumor to organ ratios at 24 hours (similar to 
WT) and could be well suited for optical imaging or MRI one day after construct 
administration. Var3 might also be suitable for fluorescence-guided surgery, marking 
a tumor with fluorescently-labeled pHLIP and performing surgery on the next day, 
when the contrast index is the highest. Var7 is one of the truncated versions of pHLIP, 
which could be appropriate for SPETC/PET imaging, since it demonstrates fast tumor 
targeting and blood clearance. 
 
In this report, we show that the biophysical principles that guide pHLIP peptide 
interactions with lipid bilayers can be used to determine peptide performance in vivo, 
and we identify two pHLIP variants as appropriate candidates for uses in clinical 
imaging of acidic tissues, such as solid tumors. 
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Figure 1. Titration of pHLIP variant binding to liposomes at high and low pHs. 
The titration of the pHLIP variants with increasing concentration of POPC liposomes 
at pH8 (a) and pH4-5 (b) are followed using intrinsic peptide fluorescence changes. 
For comparison the mole-fraction partition coefficients for Var0 (WT-pHLIP) at pH8 
and 5 are 4.87x10
4
 and 1.54x10
6
, respectively, and the corresponding Gibbs free 
energies are 6.04 and 7.98 kcal/mol. 
 
 
Figure 2. pH-dependent bilayer insertion of variants. Peptide intrinsic fluorescence 
changes are used to follow the insertion as a function of pH (transition from the state 
II to state III as the pH is lowered).  
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Figure 3. Kinetics of insertion. Representative kinetic curves for the insertion of 
variant peptides into the lipid bilayer are shown, the characteristic time of insertion of 
Var0 (WT-pHLIP) is about 40 sec. 
 
 
Figure 4. Tumor to organ fluorescence ratios. Tumor to muscle, tumor to kidney, 
and tumor to liver ratios calculated at 4 and 24 hour time points are shown for all 
pHLIP variants. 
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Figure 5. Comparisons with control K-pHLIPs. The CD (a) and tryptophan 
fluorescence (b) spectra of K-Var3 and K-Var7 show that these variants lose the 
ability to interact with a lipid bilayer in a pH-dependent manner. (c-d) Cellular uptake 
at pH7.4 and 5.9 of Var3, K-Var3, Var7, and K-Var7 labeled with Rhodamine are 
shown. The cellular uptake of four peptides labeled with BODIPY are shown at both 
pHs in Supplementary Figure S4. (e-f) Whole-body NIR fluorescence images of mice 
obtained at 4 and 24 hours after i.v. administration of Var3, K-Var3 (e) and Var7, K-
Var7 (f) conjugated with Alexa750. The tumor is indicated by arrows on the NIR 
images as reported by the GFP signal shown in adjacent images. Images obtained at 
different time points are presented with maximum contrast, the contrast-to-noise ratios 
are: Var3, 4h – 103; Var3, 24h – 186; Var7, 4h – 85; Var7, 24h – 360; K-Var3, 4h – 
87; K-Var3, 24h – 54; K-Var7, 4h – 22; K-Var7, 24h – 16. (g) The A549-GFP tumor 
to muscle ratios calculated for 4 hours for BODIPY-pHLIPs and -K-pHLIPs and 
HeLa-GFP tumor to muscle ratios calculated for 4 and 24 hours time points for 
Alexa750-pHLIPs and -K-pHLIPs are shown. The mean fluorescence of HeLa-GFP 
and A549-GFP tumors and organs at 4 and 24 hours after Alexa750-K-pHLIPs and at 
4 hours after BODIPY-pHLIPs and -K-pHLIPs administration are given in the 
Supplementary Table S4 and S5, respectively. 
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SUPPLEMENTARY DATA 
MATERIALS AND METHODS 
Conjugation of pHLIP variants with fluorescent dyes 
The lyophilized powder of a peptide was dissolved in a solution containing 3M urea, 
and the peptide solution was transferred to buffer using a G-10 size-exclusion spin 
column, or was dissolved directly in phosphate buffer at pH8 for biophysical studies. 
The concentrations of the peptides were determined by absorbance (for Var0-2 and 
Var14-16: ɛ280 = 13,940 M
-1
 cm
-1
; and for Var3-13 and K-Var3, K-Var7: ɛ280 = 12,660 
M
-1
 cm
-1
).  
 
For studies on cultured cells and animals, each pHLIP variant was conjugated with 
AlexaFluor
 
750 C5-maleimide (Invitrogen, catalog #A30459), and Var3, Var7, K-
Var3, and K-Var7 were conjugated with Tetramethylrhodamine-5-maleimide, single 
isomer (Invitrogen, catalog #T6027) or BODIPY-TMR C5-maleimide (Invitrogen, 
catalog #B30466) in DMF or DMSO at a ratio of 1:1.1 of dye:peptide and incubated at 
room temperature for about 6 hours and then at 4ºC until the conjugation reaction was 
completed. The reaction progress was monitored by reverse phase HPLC. The purity 
of products was assessed by analytical HPLC and peak identity was confirmed by 
SELDI-TOF mass spectrometry.  
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Liposome preparation 
Large unilamellar vesicles (LUVs) were prepared by extrusion. POPC (1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids, Inc.) dissolved in 
chloroform at a concentration of 1 mg/ml were desolvated on a rotary evaporator and 
dried under high vacuum for several hours. The phospholipid film was then rehydrated 
in 100 mM phosphate buffer, pH8.0, vortexed for 2 hours, and repeatedly extruded 
through membranes with 100 or 50 nm pore sizes to obtain LUVs.  
 
Oriented circular dichroism measurements 
Oriented circular dichroism (OCD) was measured from supported bilayers deposited 
on a stack of quartz slides with special polish for far UV measurements, with spacers 
of 0.2 mm thickness on one side of each slide (Starna). Quartz slides were cleaned by 
sonication for 10 min in cuvette cleaner solution (Decon Contrad 5% in water), 2-
propanol, acetone, 2-propanol, and rinsed with deionized water. Then the slides were 
immersed in a mixture of concentrated sulfuric acid and hydrogen peroxide (ratio 3:1) 
for 5-10 min to completely remove any remaining organic material from the slides. 
Slides were then thoroughly rinsed with and stored in deionized water (Milli-Q 
purified water kept at 25 °C). A POPC lipid monolayer was deposited on the clean 
quartz substrate by the Langmuir-Blodgett (LB) method using a KSV minitrough. For 
the LB deposition, a POPC lipid solution in chloroform was spread on the subphase 
and allowed to evaporate chloroform for about 30 min, followed by monolayer 
compression to 32 mN/m. An initial layer was deposited by retrieving the slide from 
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the subphase at a rate of 15 mm/min. The second layer of the bilayer was created by 
fusion. For this step, the monolayer on the slide was incubated with a solution of 
POPC vesicles (50 nm in diameter obtained by extrusion) mixed with the peptide 
solution at pH4 (0.5 mM POPC and 10 μM peptide). The fusion occurred during 6 
hour incubation at 100% humidity. Then, excess vesicles were carefully removed and 
the slides were stacked to make a pile filled with the peptide solution (5 μM) at pH4. 
Bilayers with the peptide solution were allowed an additional 6 hour equilibration. 
Measurements were taken at 3 steps during the process:  when the monolayers were 
incubated with the excess of liposomes, soon after spaces between slides were filled 
with the peptide solution, and 6 hours after the second measurement. 14 slides (28 
bilayers) were assembled and OCD spectra were recorded on a MOS-450 spectrometer 
with 2 s sampling time. Control measurements were carried out of the peptide between 
slides with and without supported bilayers and in the presence of an excess of POPC 
liposomes. 
 
Assumptions made for the analysis of pH-dependence data 
Peptide intrinsic fluorescence changes are used to follow the insertion as a function of 
pH (transition from the state II to state III as the pH is lowered). Decomposition of the 
fluorescence spectra measured at various pHs gives the positions of the maxima, and 
the single component solutions are shown. The Henderson-Hasselbalch equation with 
cooperativity was used to fit the experimental points, and the fitting curves and 95% 
confidence intervals are shown by the red and blue lines, respectively. Each graph 
notes the apparent pK of the peptide’s insertion into the membrane obtained from the 
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fitting of the experimental data. The pKa of Var0 (WT-pHLIP) is 6.0. The pKa values 
obtained by fitting of the experimental data by the Henderson-Hasselbalch equation 
with a fixed cooperativity parameter (n=1) are very similar to the data shown in the 
figure:  Var1=6.14; Var2=5.59; Var3=5.09; Var4=5.32; Var5=4.84; Var6=5.06; 
Var7=5.51; Var8=5.75; Var9=5.59; Var10=4.92; Var11=5.52; Var12=4.52; 
Var13=5.16; Var14=5.69; Var15=5.59; Var16=5.63. It is assumed that there is a linear 
relation between the position of the maximum and the contribution of state II (or state 
III) (state I is the peptide in solution at pH8; state II is the peptide in the presence of 
POPC liposomes at pH8; state III is the result of folding and insertion of the peptide 
with POPC when the pH is dropped from 8 to 3.6 by the addition of an aliquot of 
HCl). However, due to the fact that the quantum yields in states II and III are slightly 
different, there was a slight non-linearity, so we completed the analysis by estimating 
the contributions of the states for WT-pHLIP and found that the apparent pK shifts no 
more than on 0.05 pH units toward lower pHs. Since this shift is less than the 
experimental error, we present the pKa values for transitions from the state II to III 
based on the analysis of the positions of spectral maxima. 
 
Quantification of cellular uptake 
For quantification of cellular uptake of BODIPY-labeled Var3 and Var7 at pH7.4 and 
5.9 we used A549-GFP cells in suspension. 2 μM of fluorescently labeled peptides 
were incubated with cells in DMEM media at pH7.4 and 5.9 for 30 min at 37°C and 
5% CO2. Then, cells were pelleted by centrifugation (2000 rpm, 4 min) at room 
temperature, the supernatant was removed and the pellet was washed three times with 
35 
 
the same media and resuspended in 50 µL, and the cell suspension solution was placed 
into cell counting chambers. The phase-contrast, GFP fluorescent, and BODIPY 
fluorescent signals were measured and analyzed using ImagePro Plus. 
 
Biophysical properties, which affect tumor targeting 
- The apparent pK of peptide insertion into membrane determines the proportion of 
available peptide molecules inserted into plasma membrane of cancer cells at various 
pHs. Currently we have pHLIP peptides with pKas varying over the range from 4.5 to 
6.5 for insertion into POPC lipid bilayers. Various pHLIP variants might be used to 
probe the pHs of more or less acidic tumors. The insertion of pHLIP responds to the 
pH at the surfaces of cancer cells, not that of the surrounding fluid. Due to the 
transmembrane potential gradient, protons accumulate at the surfaces of cells in close 
vicinity of membrane, and the pH is lower than in the bulk extracellular environment 
or in blood. Current methods of measuring pH in vivo report the average value of 
extracellular pH in tumors, which can vary from 6.0 to 7.2, but the pH at the surfaces 
of cancer cells are likely to be lower. 
- pHLIP is a relatively hydrophobic peptide, therefore significant initial association with 
a lipid bilayer or plasma membrane occurs at neutral pH. The strength of this 
interaction (state II) is determined by the balance of hydrophobic and polar/charged 
residues in the pHLIP sequence. Stronger partitioning of the peptides onto bilayers at 
neutral pH increases the time of circulation in the blood. A long circulation time is a 
disadvantage for SPECT/PET imaging, since the short half-life-time probes are used 
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and tumor targeting and blood clearance need to be very fast (at least within 4 hours). 
However, long circulation times of pHLIP variants in the blood could be very well 
suited for fluorescence or MR imaging, as well as for the delivery of therapeutic 
agents. We find that all pHLIP variants that have higher affinities for membranes at 
neutral pH show high tumor/organ ratios at 24 hours post-injection. 
- An important parameter is the difference between the Gibbs free energy of peptide 
binding to membranes at low pH vs. high pH. This parameter reflects the difference in 
the affinity of the peptide to the membrane at low and neutral pH, as well as the 
strength of the formation of TM helix at low pH. A larger ΔΔG will ensure a greater 
differentiation between the inserted and non-inserted peptides as a function of pH. 
-  For applications in vivo, the kinetics of peptide insertion across the lipid bilayer are 
important for rapid equilibration with tissues and clearance from the blood. Based on 
insertion kinetics we can group all pHLIP peptides into:  i) the peptides with 
protonatable residues both in the TM and in the inserting end show the slowest 
kinetics of insertion (minutes); ii) peptides that are truncated at the inserting end and 
have few or no protonatable residues at the inserting end, partition in bilayer much 
faster (seconds); iii) peptides that have protonatable residues at the inserting end but 
not in the TM show intermediate times of insertion (~20 s); and finally, peptides with 
only one protonatable residue in the TM have the fastest kinetics of insertion, which 
coincides with time of formation of helical structure (~100 msec).  
- Exit kinetics should be different in cells and liposomes, since peptides that have 
protonatable residues that are translocated across a cell membrane move them to the 
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neutral pH of the cytoplasm. To exit the cell membrane, these groups must be 
protonated, which is much less likely in the cytoplasm, so these peptides become 
anchored in a cell. Such an “anchor” can significantly (by orders of magnitude) 
reduce the rate of peptide exit, and the peptide could stay in the plasma membrane for 
weeks. Such an effect would explain our observation that mouse tumors are stably 
labeled with fluorescent WT-pHLIP. 
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FIGURES 
 
Figure S1. Three states of pHLIP variants. The pHLIP variants were studied for 
the presence of the three basic states of pHLIP:  state I is the peptide in solution at 
pH8; state II is the peptide in the presence of POPC liposomes at pH8; state III is the 
folding and insertion of the peptide with POPC when the pH is dropped from 8 to 3.6 
by the addition of an aliquot of HCl. The states are monitored by changes of the 
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steady-state tryptophan fluorescence at λex=295 nm (a) and CD (b) spectroscopic 
signals. The concentrations of the peptides and POPC were 7 µM and 1.5 mM, 
respectively. State I: in aqueous solution at pH8 and in the absence of lipids, all 
variants except Var16 (and to some degree Var1) have long wavelength emission 
maxima and are largely unstructured. Further, the addition of several Asp residues to 
the N-terminus (Var15) significantly increases peptide solubility compared to a similar 
sequence investigated previously, which has no Asp at the N-terminus. State II: when 
liposomes are added to the solution, the majority of the peptide is bound at the surface 
of the membrane, as observed by a shift of the emission maxima to shorter 
wavelengths and an increase of fluorescence intensity. In the cases of Var4, 15, and 
16, partial formation of alpha-helical structure is seen, while all other pHLIP variants 
are predominantly unstructured. State III: when the pH is lowered, we observe the 
formation of a helical structure and further propagation of tryptophan residues into the 
membrane, reflected by a further blue shift of the fluorescence maximum and a further 
increase of intensity relative to State II, with the single exception of Var4. There is 
some variation in the positions of the maxima and the increases of intensity in states II 
and III for different peptides, which could result from differences in the positioning of 
the tryptophan fluorophores as a result of the sequence changes. The strength of the 
helical signal is smallest for Var12 and 13 in State III, which most probably have less 
stable TM configurations given their lengths. For the variants 1, 2, 3, 7, 15, and 16, the 
oriented circular dichroism (OCD) signal was measured at low pH on supported 
bilayers (green curves). In each case the helical orientation was found to be TM.  
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Figure S2. Comparison of the kinetics of WT-pHLIP and Alexa750-WT-pHLIP 
insertion into the membrane. The changes of tryptophan fluorescence signal of 
Alexa750-WT-pHLIP in the presence of POPC liposome in a result of pH drop from 8 
to 4-5 was recorded in a stopped-flow apparatus, multiplied by (-1), normalized, and 
compared with the kinetics of insertion of non-labeled WT.  
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Figure S3. Distribution of Alexa750-pHLIP in organs and tumors. Normalized 
mean NIR fluorescence of tumor and organs at 4 and 24 hours after construct 
administration are shown (the signals in kidney at 4 hours are taken as 100%). The 
non-normalized values of fluorescence are given in Supplementary Tables S2 and S3. 
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Figure S4. Cellular uptake of BODIPY labeled Var3, Var7, K-Var3, and K-Var7. 
Fluorescence and phase-contrast images of cells treated with fluorescence peptides at 
pH7.4 and 5.9 for 30 min and washed 4-5 times of the same media are shown. Also, 
cell experiments were carried out with Alexa750-labeled Var3, Var7, K-Var3, and K-
Var7. Despite the fact that the signal was low (due to the low NIR sensitivity of the 
Retiga CCD camera) the distribution of the signal in cells was the same as in the case 
of Rho and BODIPY-labeled peptides. 
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TABLES 
Parameters Name State I State II State III Name State I State II State III 
 
 
 
max 
S 
225 x10
3
 
 
Var1 
349 345 339  
Var9 
353 350 339 
1 1.47 1.81 1 1.28 2.10 
-2.42 -3.85 -9.46 -2.39 -3.20 -7.90 
 
Var2 
 
350 345 342  
Var10 
350 347 340 
1 2.08 2.76 1 1.47 2.86 
-2.74 -3.76 -8.64 -2.40 -2.46 -8.40 
 
Var3 
353 347 338  
Var11 
351 345 340 
1 1.66 2.08 1 2.60 3.20 
-2.07 -3.94 -13.49 -2.14 -3.08 -9.02 
 
Var4 
353 340 345  
Var12 
353 352 341 
1 2.66 3.32 1 1.36 2.90 
-2.32 -10.14 -15.28 -0.82 -0.96 -4.80 
 
Var5 
 
351 355 340  
Var13 
355 349 340 
1 2.05 3.52 1 1.72 3.61 
-2.20 -3.38 -6.25 -1.76 -2.28 -6.14 
 
Var6 
 
353 350 339  
Var14 
351 346 344 
1 0.96 1.64 1 1.54 2.94 
-2.12 -2.89 -6.95 -2.00 -3.79 -9.91 
 
Var7 
 
352 345 340  
Var15 
351 339 339 
1 1.74 3.08 1 2.14 2.52 
-2.64 -4.12 -8.82 -4.30 -8.94 -10.08 
 
Var8 
353 353 337  
Var16 
346 345 339 
1 1.19 2.48 1 1.89 2.14 
-0.89 -1.22 -9.43 -5.41 -7.03 -8.57 
 
Table S1. The three states of each pHLIP variant. The spectral parameters of the 
pHLIP variants in states I, II, and III are presented. The parameters were obtained 
from analysis of the fluorescence and CD spectra shown in Figure 1. The maximum 
position of the fluorescence spectrum, max, in nm; S is the normalized area under the 
spectra (normalization was done on the area under the spectrum in State I); 225 x 10
3
, 
deg cm
2
 dmol
-1
 – the molar ellipticity at 225 nm. 
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 Var0-WT 
n = 9 
Var1-2D1D 
n = 6 
Var2-2D1D 
n = 5 
Var3-3D 
n = 7 
Var4-3E 
n = 4 
Var5-3Da 
n = 5 
Kidney 
Tumor 
Heart 
Lungs 
Liver 
Spleen 
Bladder 
Stomach 
Intestine 
Muscle 
Brain 
3630.6485.6 
1373.8334.5 
621.4152.3 
1003.6297.5 
1651.4470.2 
546.4131.4 
825.4495.8 
909.2277.1 
884.2260.5 
476.8110.1 
270.146.3 
4324.0444.6 
1812.4819.0 
752.9398.4 
1016.6567.7 
2309.71457.0 
757.5445.0 
1030.5646.3 
1249.6783.1 
1116.4646.0 
766.5285.3 
303.1113.3 
3456.3585.4 
1145.3737.5 
554.6421.2 
761.1506.8 
1432.4950.8 
539.3372.3 
665.3486.4 
1092.0793.5 
590.9347.0 
413.7248.9 
233.572.9 
6125.61004.1 
3054.9726.2 
855.0331.6 
803.1256.2 
1829.6741.6 
675.6244.6 
1104.6628.7 
1029.6355.0 
574.3221.9 
541.9180.3 
350.695.6 
6755.6698.7 
2439.3443.2 
980.5187.3 
1077.384.2 
3615.31099.4 
987.3320.8 
1198.8719.3 
1239.8438.8 
888.5442.9 
629.897.9 
372.313.9 
3097.0528.3 
559.495.6 
334.043.4 
405.434.5 
561.2103.0 
432.263.0 
452.447.6 
470.871.7 
257.623.0 
250.617.9 
193.213.5 
 
 Var6-3Db 
n = 5 
Var7-3Ea 
n = 16 
Var8-3Eb 
n = 5 
Var9-3Ec 
n = 5 
Var10-2D 
n = 6 
Var11-2E 
n = 6 
Kidney 
Tumor 
Heart 
Lungs 
Liver 
Spleen 
Bladder 
Stomach 
Intestine 
Muscle 
Brain 
2536.1297.2 
461.671.6 
262.229.5 
266.423.7 
414.831.8 
316.050.6 
298.638.3 
268.631.2 
246.435.0 
220.830.0 
180.218.7 
3583.3427.9 
970.1449.1 
351.181.0 
413.3135.6 
695.1244.2 
479.3310.6 
554.4243.4 
605.6205.6 
437.8109.2 
277.867.2 
206.336.0 
3729.2749.0 
910.6180.1 
515.0284.4 
526.062.2 
938.279.2 
443.886.8 
608.8113.3 
563.493.3 
380.687.7 
339.050.7 
230.218.4 
3367.9667.6 
1169.4297.9 
613.4250.6 
958.0367.2 
1309.2255.3 
629.296.1 
942.0204.0 
934.2251.3 
471.898.9 
450.897.8 
222.016.7 
3575.0540.4 
819.9306.7 
341.587.7 
412.842.4 
539.0114.3 
423.429.3 
420.077.3 
513.170.2 
321.6109.2 
281.570.0 
217.426.4 
4164.3833.5 
981.0357.9 
532.3104.5 
560.242.2 
744.257.1 
495.746.5 
623.0145.3 
763.0107.8 
353.314.7 
330.222.2 
241.524.7 
 
 Var12-1D 
n = 7 
Var13-1E 
n = 6 
Var14-Rev 
n = 5 
Var15-2N 
n = 5 
Var16-2P 
n = 6 
Kidney 
Tumor 
Heart 
Lungs 
Liver 
Spleen 
Bladder 
Stomach 
Intestine 
Muscle 
Brain 
2004.5527.7 
614.5186.7 
368.7100.4 
423.8122.0 
435.9139.0 
295.775.5 
287.251.5 
341.284.6 
227.559.0 
270.830.7 
207.033.0 
2653.7357.1 
459.099.3 
351.761.5 
349.778.9 
457.246.8 
365.220.4 
414.7102.9 
483.396.1 
277.831.1 
261.824.4 
211.013.5 
4162.9210.7 
1245.0308.7 
691.0104.7 
808.2116.3 
1863.0312.6 
527.864.6 
648.6235.5 
685.6101.3 
839.8196.9 
421.435.8 
290.627.2 
5657.0843.8 
2075.8252.2 
837.6188.0 
1190.8419.3 
1888.8303.1 
717.461.9 
743.659.8 
556.694.6 
720.452.9 
500.637.1 
405.065.5 
3733.0582.9 
1407.0142.1 
342.728.9 
451.085.2 
1344.0153.2 
370.724.0 
525.7121.2 
361.261.5 
403.367.3 
396.037.8 
216.714.9 
 
Table S2. Mean near infrared fluorescence with SD calculated for each organ 
collected at 4 h after Alexa750-pHLIP variant administration. The mean 
fluorescence values of organs were normalized to the signal in kidney for each mouse 
and then averaged for each variant; they are presented in Figure S3. n is number of 
animals. 
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 Var0-WT 
n = 9 
Var1-2D1D 
n = 4 
Var2-2D1D 
n = 9 
Var3-3D 
n = 7 
Var4-3E 
n = 3 
Var5-3Da 
n = 5 
Kidney 
Tumor 
Heart 
Lungs 
Liver 
Spleen 
Bladder 
Stomach 
Intestine 
Muscle 
Brain 
854.4186.9 
818.8157.4 
248.533.3 
355.738.8 
602.2104.4 
226.113.0 
250.227.5 
248.933.1 
270.240.5 
197.631.0 
166.310.8 
3349.52262.1 
1366.1776.7 
580.9280.2 
758.3422.8 
2211.1973.9 
626.3368.0 
861.6743.0 
884.0619.8 
808.7473.3 
555.4320.9 
253.573.8 
1525.2472.4 
881.4560.6 
240.394.3 
351.9190.9 
660.8427.5 
285.3170.8 
301.3183.5 
353.2178.4 
237.275.3 
213.588.9 
164.830.8 
1141.8416.7 
950.9434.1 
186.031.3 
190.431.8 
366.372.0 
199.025.5 
221.633.2 
198.418.2 
184.319.5 
158.721.6 
147.78.1 
1151.4262.4 
1106.3651.1 
255.075.1 
287.793.6 
737.390.4 
249.330.7 
282.372.8 
257.028.0 
261.334.8 
185.345.1 
163.024.3 
431.0121.5 
252.267.6 
166.016.0 
198.615.3 
209.018.2 
184.014.5 
188.010.8 
201.816.3 
141.62.1 
141.45.1 
136.83.2 
 
 Var6-3Db 
n = 5 
Var7-3Ea 
n = 17 
Var8-3Eb 
n = 5 
Var9-3Ec 
n = 5 
Var10-2D 
n = 5 
Var11-2E 
n = 4 
Kidney 
Tumor 
Heart 
Lungs 
Liver 
Spleen 
Bladder 
Stomach 
Intestine 
Muscle 
Brain 
380.546.0 
218.640.8 
142.84.9 
148.88.4 
220.25.7 
164. 69.0 
156.010.8 
152.04.3 
141.43.8 
134.21.8 
137.62.9 
785.3200.9 
453.1173.2 
173.320.3 
181.624.2 
299.851.7 
200.122.6 
187.223.5 
185.826.2 
207.828.9 
154.515.0 
147.87.5 
1287.1307.6 
441.6102.0 
201.819.8 
330.276.0 
455.676.9 
244.839.1 
236.837.7 
249.459.1 
192.614.2 
171.615.7 
154.66.7 
1242.2280.6 
441.253.9 
247.092.6 
270.658.6 
536.0101.4 
273.67.3 
264.230.6 
258.238.2 
233.019.8 
182.28.1 
159.07.4 
1013.5104.4 
345.1140.2 
196.879.3 
198.417.3 
338.347.5 
217.071.8 
207.460.2 
227.989.2 
194.473.3 
180.664.6 
165.530.7 
828.6129.1 
400.361.0 
186.310.6 
207. 38.7 
285.512.4 
204.315.1 
214.318.2 
198.59.3 
173.09.5 
173.06.1 
157.82.6 
 
 Var12-1D 
n = 6 
Var13-1E 
n = 3 
Var14-Rev 
n = 5 
Var15-2N 
n = 5 
Var16-2P 
n = 6 
Kidney 
Tumor 
Heart 
Lungs 
Liver 
Spleen 
Bladder 
Stomach 
Intestine 
Muscle 
Brain 
469.872.1 
323.793.8 
202.723.7 
221.130.7 
252.332.9 
165.898.0 
242.726.6 
197.423.9 
166.720.0 
184.628.2 
159.517.9 
444.988.9 
218.315.1 
157.76.7 
184.78.3 
224.021.9 
158.310.4 
188.016.6 
170.311.7 
152.712.1 
147.77.4 
146.72.5 
1157.4147.5 
867.4286.1 
230.823.7 
285.467.0 
567.2130.6 
221.640.7 
274.636.8 
189.822.2 
289.472.0 
188.825.9 
168.614.0 
1618.9283.3 
1416.0468.6 
370.852.3 
473.268.9 
742.850.2 
295.834.5 
417.626.6 
288.655.5 
296.036.8 
260.814.3 
214.29.3 
819.3124.1 
575.5231.1 
164.220.1 
171.329.5 
421.552.7 
183.313.9 
166.711.2 
166.520.7 
168.37.1 
147.07.4 
145.06.9 
 
Table S3. Mean near infrared fluorescence with SD calculated for each organ 
collected at 24 h after administration of Alexa750-pHLIP variants. The mean 
fluorescence values of each organ were normalized to the signal in kidney at 4 h 
(Table S2) for each mouse and then averaged for each variant; they are presented in 
Figure S3. n is the number of animals. 
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 K-Var3, 4h 
n = 11 
K-Var3, 24h 
n = 8 
K-Var7, 4h 
n = 10 
K-Var7, 24h 
n = 10 
Kidney 
Tumor 
Heart 
Lungs 
Liver 
Spleen 
Bladder 
Stomach 
Intestine 
Muscle 
Brain 
921.6306.2 
395.9107.6 
319.6140.2 
296.166.9 
2637. 6446.4 
1057.5416.6 
331.1100.1 
286.270.0 
298.746.0 
201.329.9 
192.525.9 
254.591.9 
220.070.0 
165.451.1 
154.116.0 
684.2138.5 
284.332.0 
176.526.7 
168.420.2 
173.914.5 
141.115.6 
139.75.9 
852.5345.0 
306.0107.6 
228.256.2 
225.080.0 
1920.4752.3 
552.3140.8 
265.470.9 
260.684.0 
289.784.9 
178.831.4 
158.828.5 
235.215.5 
185.79.8 
156.427.7 
136.210.7 
538.265.2 
255.280.1 
155.311.0 
156.715.5 
166.99.7 
127.74.2 
134.32.9 
 
Table S4. Mean near infrared fluorescence with SD calculated for each organ 
collected at 4 and 24 h after Alexa750-K-pHLIP variant administration. n is the 
number of animals.  
 
 Var3, 4h 
n = 4 
K-Var3, 4h 
n = 4 
Var7, 4h 
n = 4 
K-Var7, 4h 
n = 4 
Kidney 
Tumor 
Heart 
Lungs 
Liver 
Spleen 
Bladder 
Stomach 
Intestine 
Muscle 
Brain 
154.314.4 
325.011.4 
128.38.1 
127.511.4 
391.578.9 
122.03.9 
241.723.8 
257.066.2 
197.826.7 
150.56.8 
142.013.0 
128.810.6 
151.516.7 
114.56.0 
116.07.0 
152.819.8 
118.34.5 
150.819.3 
233.075.2 
159.042.3 
126.83.0 
135.311.8 
189.551.0 
308.0115.8 
124.013.1 
124.011.6 
210.567.6 
125.010.4 
233.064.6 
269.876.6 
222.5118.3 
141.020.5 
131.523.5 
121.34.6 
136.39.3 
111.53.5 
111.01.4 
142.330.5 
113.04.2 
143.818.8 
212.526.6 
133.019.3 
119.34.8 
130.57.9 
 
Table S5. Mean near infrared fluorescence with SD calculated for each organ 
collected at 4 h after BODIPY-labeled Var3, K-Var3, Var7, and K-Var7 
administration. n is the number of animals.  
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ABSTRACT 
We develop a method for pH-dependent fusion between liposomes and cellular 
membranes using pHLIP
 
(pH (Low) Insertion Peptide), which inserts into lipid 
bilayer of membrane only at low pH.  Previously we establish the molecular 
mechanism of peptide action and show that pHLIP can target acidic diseased tissue. 
Here we investigate how coating of PEGylated liposomes with pHLIP might affect 
liposomal uptake by cells. The presence of pHLIP on the surface of PEGylated-
liposomes enhanced membrane fusion and lipid exchange in a pH dependent fashion, 
leading to increase of cellular uptake and payload release, and inhibition of cell 
proliferation by liposomes containing ceramide. A novel type of pH-sensitive, 
“fusogenic” pHLIP-liposomes was developed, which could be used to selectively 
deliver various diagnostic and therapeutic agents to acidic diseased cells. 
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INTRODUCTION 
Liposomes are widely used nanocarries that allow encapsulation of various 
therapeutics and diagnostic agents [1]. Once internalized by cells, liposomes must 
disrupt or fuse with the endosomal membrane in order to release the payload into the 
cytoplasm. Endosomal trapping of liposomes (and their contents within) pose a 
significant challenge to cytoplasmic delivery of the drug payload. Thus, pH-sensitive 
functionalities have been incorporated into liposomes to promote the mixing of lipids 
(between the liposome and the endosomal membrane) under the acidic environment of 
the endosomes, which in turn facilitates payload release into the cytoplasm [2-8]. 
Meanwhile, to mask against opsonization and to increase circulation time in blood, 
liposomes are usually coated with poly(ethyleneglycol) (PEG) polymers [9-12]. 
Unfortunately, the presence of PEG on the surface of liposomes hinders drug release, 
even when liposomes have been internalized via receptor mediated endocytosis [13]. 
One approach to avoid this difficulty is to use pH-sensitive PEG polymers that 
disassemble in the endosomal low pH environment, thus exposing lipid bilayer 
membrane of the liposome for direct interaction with the membrane of the endosome 
[2, 6, 14].  
 
Liposomes can be fashioned into targeted drug carriers. Current targeting strategies 
usually involve conjugation of liposomes with antibodies or other ligands. However, 
these methods have limitations due to the heterogeneous expression of the targeted 
receptors in diseased tissues. Alternatively, we have developed a nanotechnology 
platform to target the microenvironment of diseased tissues. One of the common 
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characteristics of diseased tissues (cancerous tumors, ischemia, inflammation, arthritis, 
atherosclerosis) is an acidic extracellular environment. We designed peptides that 
insert into cellular membranes under slightly acidic pH but not at normal pH. These 
peptides, called pHLIP

 peptides (pH (Low) Insertion Peptides), demonstrated a high 
ability of targeting acidic tissues in vivo, (including tumors, arthritic sites, and 
ischemic myocardium)[15-19]. The targeting mechanism of pHLIP is based on its pH-
triggered insertion into lipid bilayers that ultimately results in the formation of a 
transmembrane helix [20-23]. One promising application is to use pHLIP for targeting 
liposomes towards diseased tissues. Here, new formulations of pH-sensitive, 
“fusogenic,” PEGylated liposomes are developed by including pHLIP in the liposomal 
coating. We demonstrated that pHLIP-PEG-liposomes bind and fuse with cellular 
membranes at low pH, but not at normal pH, and promote cellular uptake. 
 
MATERIALS AND METHODS 
Materials  
The N-capped pHLIP peptide,  
Acetyl-NH-ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT-CO2H, was 
prepared by standard solid phase synthesis and purified at the W.M. Keck Foundation 
Biotechnology Resources Laboratory at Yale. The lipids, 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),  
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (ammonium salt) 
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(DSPE-PEG2000-Maleimide), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000), 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-[lissamine rhodamine B sulfonyl] (Rhod-PE), N-octanoyl-
sphingosine-1-{succinyl[methoxy(polyethylene glycol)750]} (C8-PEG750 ceramide) 
and N-hexanoyl-D-erythro-sphingosine (C6 Ceramide), were purchased from Avanti 
Polar Lipids, Inc (Alabaster, AL). The fluorescein labeled lipids, N-(fluorescein-5-
thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, 
triethylammonium salt (FITC-DHPE), rhodamine labeled fatty acid, octadecyl 
rhodamine B chloride (R18), and fluorescent dyes: Wheat germ agglutinin Texas Red, 
ER-tracker green, mito-tracker deep red, 8-aminonaphthalene-1,3,6-trisulfonic acid, 
disodium salt (ANTS), and p-xylene-bis-pyridinium bromide (DPX) were from Life 
Technologies (Carlsbad, CA) . The fatty acid conjugated with 1.4 nm gold 
nanoparticles, palmitoyl nanogold, and HQ Silver
TM
 Enhancement Kit were purchased 
from Nanoprobes, Inc (Yaphank, NY). DNA staining dye, propidium iodide (PI), was 
from Sigma-Aldrich Co, LLC (St. Louise, MO). 
 
Synthesis of DSPE-PEG2000-pHLIP 
DSPE-PEG2000-pHLIP was synthesized by the covalent conjugation of DSPE-PEG2000-
maleimide with the single cysteine residue at the N-terminus of pHLIP. In a typical 
coupling reaction, 600 nmol of peptide was mixed with 500 nmol of DSPE-PEG2000-
Maleimide in 200 µL of methanol and left for overnight stirring at room temperature 
under argon. The existence of the product was ensured by SELDI-TOF mass-
spectrometry analysis. 
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Liposome preparation  
Liposomes were prepared by extrusion. A chloroform solution of the desired lipid 
mixture (1 μmol) including solution of DSPE-PEG2000-pHLIP in methanol was 
vortexed and evaporated using rotary evaporator, producing an even thin film. pHLIP 
is an unstructured peptide, which could be dissolved in organic solvents including 
methanol and chloroform. The lipid film was left under a vacuum for overnight to 
remove residuals of organic solvent. The hydration of the dry lipid film was 
accomplished by adding 1 mL of stock buffer solution (10 mM phosphate, 150 mM 
NaCl, pH 8) to the flask of lipids and agitating. Typically, a hydration time of 1 hr 
with vigorous vortexing was needed for pHLIP-containing liposome. After 10 freeze-
thaw-vortex cycles, the resulting multilamellar liposome solution was extruded 15 or 
31 times through 50, 100, or 200 nm polycarbonate filters and sterilized by filtering 
through 0.2 μm filter. The final lipid concentration was re-calculated by knowing the 
concentration of fluorescent lipids, which was obtained spectrophotometrically. Small 
amount of liposomes were diluted in methanol and absorbance of rhodamine 
(ε556=125,000 M
-1
cm
-1
)
 or fluorescein (ε495=88,000 M
-1
cm
-1
) was measured. When 
loading with propidium iodide (PI), ANTS, or DPX was required, PI (4 mM), ANTS 
(25 mM), or DPX (90 mM) were added as a component of the rehydration solution. 
After liposome extrusion, free PI, ANTS, or DPX were removed by dialysis using 
dialysis tube with MWCO of 8000 Da, followed by stirring in 1 L buffer solution for 
24 hrs with 3 times buffer refreshing, or by fast spin semi-dry column using sephadex 
G25. In each case we ensure that ionic strength of solution within liposomes was the 
same as outside of liposomes. The ionic strength was regulated by addition of NaCl.  
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Cryo-electron microscopy  
About 5 µL droplet of liposome solution was spread on an electron microscopy grid 
and preserved in a frozen-hydrated state by a rapid freezing in liquid ethane. The 
vitrification process was performed via FEI Vitrobot System (Hillsboro, OR), with the 
setting of a single blot of 3 sec, an offset of -1, and drain and wait time of 1 sec. 
Samples were imaged using JEOL 2100 TEM with an accelerating voltage of 200 kV 
at magnifications of 20,000x and 40,000x. 
 
DLS measurements 
The size of liposomes was measured by dynamic light scattering (DLS) using a 
Malvern Zetasizer Nano ZS instrument with Malvern disposable cuvettes (Malvern 
USA, Southborough, MA) right after the extrusion of liposomes and in some cases, 
within a week after preparation. Samples were typically 200 nmol liposomes in 1 mL 
of aqueous buffer (10 mM phosphate, 150 mM NaCl, pH 8.0). 
 
Inter-liposomal fusion assay  
R18-labeled liposomes (50 µL, 200 µM) were mixed with an equal volume of 
unlabeled POPC vesicles (lipid concentration was varied from 0 to 6 mM) in an 
aqueous buffer (10 mM phosphate, 150 mM NaCl, pH 8.0). The R18 fluorescence 
intensity was monitored on an ISS spectrofluorometer (Champaign, IL) at excitation 
and emission wavelengths set at 556 nm, and 590 nm, respectively, as the pH was 
lowered from 8 to 4 (via addition of small amounts of HCl). A circulating water bath 
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was connected to cuvette holder to control sample temperature at 22C. Complete 
fusion and mixing of lipids was achieved via 5 freeze-thaw cycles, the fluorescence 
intensity obtained afterwards was defined as “100% fusion.” The degree of liposome 
fusion in % was calculated according to the equation: 
𝐹𝑢𝑠𝑖𝑜𝑛 = 100 ×
𝐹 − 𝐹0
𝐹𝑚𝑎𝑥 − 𝐹0
 
where F0 is the initial fluorescent intensity of liposome mixture at pH8 (no fusion), 
Fmax is the maximum fluorescent intensity of liposome mixture at pH 4 after 5 freeze-
thaw cycles (100% fusion), and F is the fluorescent intensity of liposome mixture at 
pH 4 before freeze-thaw cycles. 
 
In other fusion assay, 100 M of 50 nm DOPC liposomes of ‘5:5’ formulation 
containing 5% R18 and encapsulated with 25 mM of fluorescent dye ANTS were 
mixed with equal volume of 2 mM of 200 nm POPC liposomes encapsulated with 90 
mM of DPX, which is a quencher of ANTS fluorescence, in the 10 mM phosphate 
buffer of pH 8 containing of 40 mM NaCl. The pH was reduced by addition of aliquot 
of concentrated HCl. The increase of R18 fluorescence signal and decrease of ANTS 
signal due to the liposome fusion and mixing of ANTS with DPX were observed on 
the same liposomes. ANTS fluorescence was excited at wavelength of 360 nm and 
observed at 530 nm.  In addition, changes of scattering signal monitored at 650 nm 
with excitation at 650 nm were recorded.  
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Cell lines 
Lung carcinoma A549 and human cervix adenocarcinoma HeLa cell lines were 
obtained from American Type Culture Collection (Manassas, VA). Cells were 
authenticated, stored according to supplier’s instructions, and used within 3-4 months 
after frozen aliquots resuscitations. Cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum, 10 μg/mL of 
ciprofloxactin in a humidified atmosphere of 5% CO2 and 95% air at 37°C. By serial 
passages some cells were adapted for the growth in low pH medium (pH 6.5). The pH 
6.5 media was prepared by mixing 13.5 g of dry DMEM powder with 0.2 g of sodium 
bicarbonate in 1 L of deionized water. 
 
Cellular uptake of fluorescently labeled liposomes 
Typically, a suspension of A549 cells was prepared by dissociating 4-6 days old 
monolayer grown in 75cm
2
 flask with trypsin, EDTA (Gibco, Gaithersburg, MD). 
Trypsinized cells were counted using a hemacytometer and diluted to 1 x 10
6
 cells/mL 
in serum-free media (for 1 hr incubation) or PBS (for 15 min incubation) as stock 
solutions. The liposomes (20 nmol), containing fluorescent probe lipids or fatty acid, 
were incubated with 2 x 10
5
 cells in 1 mL of the desired solution for 1 hr or 15 min at 
37°C or 4°C.  In some studies, ATP-depleting media (DMEM + 20 mM NaN3/ 50 mM 
2-deoxy-glucose) was added for 1 hr at 37°C prior to liposome addition and was kept 
throughout the liposome incubation period. After incubation, the cells were pelleted by 
centrifugation (2000 rpm, 4 min) at room temperature (or 4°C). Then the supernatant 
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was removed and the pellet was resuspended in 1 mL of fresh serum-free media (or 
PBS) and centrifuged second time. The second pellet was resuspended in 100 µL of 
the same media. Sequentially, 20 µL of the cell suspension solution was loaded into a 
counting chamber and the fluorescent signal of individual cells was measured using 
Nexcelom Cellometer Vision (Lawrence, MA). For each measurement, fluorescent 
data of 2000-3000 cells were obtained and statistically analyzed. All samples were 
prepared at least in triplicate for each formulation of liposomes. The fluorescent 
signals of untreated cells were used as a common divisor for normalization of all the 
fluorescent data in each assay. Cell viability was confirmed by addition of trypan blue 
to cell sample. After cellometer counting, the residual cells were reseeded in collagen-
coated cell dishes and viewed under the microscope after 24, 48, and 72 hrs. 
 
Fluorescence microscopy 
HeLa and A549 cells adapted for low pH growth (pH 6.5 and pH 6.2, respectively) 
were seeded in collagen-coated cell dishes (5,000 and 15,000 cells/dish, respectively). 
After 24 hr the culture medium was removed and cells were incubated with 6 nmol of 
fluorescein-labeled liposome, DOPC/DSPE-PEG2000-pHLIP/DSPE-PEG2000/ 
fluorescein-DHPE (85:5:5:5) in 240 L of PBS (pH 6.3) for 1 hr at 37°C under 5% 
CO2, followed by 3 times washing with sterile PBS (pH 7.4). Sequentially, wheat 
germ agglutinin Texas Red (10 g/mL) was used to stain the plasma membranes of 
live cells for co-localization studies. For the cells treated with R18 labeled liposome, 
ER-tracker green and Mito-tracker Deep Red FM were used to stain endoplasmic 
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reticulum (ER) and mitochondria of live cells. Fluorescent images were acquired with 
a Retiga CCD camera (Qimaging, Burnaby, BC, Canada) mounted to an inverted 
Olympus IX71 microscope (Olympus America, Inc., Center Valley, PA). Fluorescent 
images from different stains were obtained in the same field of view with 
corresponding filters. 
  
Cellular uptake of nanogold labeled liposomes 
A549 cells adapted for low pH media, grown to 80-90% confluence on 8-well 
chamber slide were incubated in 200 L serum-free DMEM (pH 6.5) with 12 nmol of 
nanogold labeled liposome for 15 min at 37°C under 5% CO2. After incubation, the 
medium was removed and cells were washed three times with sterile PBS (pH7.4) and 
fixed in cold methanol for 10 min, followed by washing twice with sterile PBS 
(pH7.4) and once with distilled H2O. After air-drying, cells were treated with silver 
enhancement solution (following manufacture’s instruction) and viewed under the 
light microscope. 
 
Delivery of PI  
A549 cells adapted for low pH media were seeded in collagen-coated cell dishes 
(5,000 cells/dish). After 24 hrs, the culture medium was removed and cells were 
treated with 10 nmol of PI loaded liposome DOPE/pHLIP-PEG-DSPE/DSPE-
PEG2000/fluorescein-DHPE (85:5:5:5 or 85:0:10:5) in 100 L of serum-free DMEM 
(pH 6.5) for 1 hr at 37°C under 5% CO2. After incubation, the medium was removed 
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and cells were washed three times with sterile PBS (pH 7.4) and viewed under 
fluorescence microscope. 
 
Cytotoxicity Assay 
A549 cells grown in standard growth medium of pH 7.4 and A549 cells adapted for 
low pH (pH 6.2) growth medium were loaded in the wells of 96-well plates (~5,000 
and 7,000 cells per well, respectively) and incubated overnight. Next day cells were 
treated with increasing concentrations (0, 10, 50, 100, 200, 400 μM) of DOPE and 
DOPC/pHLIP-PEG-DSPE/DSPE-PEG2000 (85:5:5:5 or 85:0:10:5) for 2 hrs followed 
by the addition of equal volume of growth medium with 20% of serum of the same pH 
(to have 10% FBS of final concentration, since constructs were not removed). Cell 
viability was assessed after 1 and 2 days of incubation with constructs using the 
colorimetric reagent (CellTiter 96 AQueous One Solution Assay, Promega), which 
was added for 1 hr to cells followed by measuring absorbance at 490 nm. All samples 
were prepared in triplicate. 
 
Inhibition of cell proliferation by liposomal ceramide 
A549 cell suspension (160,000 cells) were incubated with 160 nmol of liposomal 
ceramide in 1 mL of 10 mM phosphate buffer (150 mM NaCl, 1 mM MgCl2 and 1 
mM CaCl2) at pH 6.1 or pH 8 for 1 hr at 37°C under 5% CO2. After incubation, cells 
were pelleted by centrifugation (2000 rpm, 4 min) at room temperature followed by 
the removal of supernatant. The pellet was resuspended in 1 mL of fresh serum-free 
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media and centrifuged second time. The second pellet was reseeded into 96-well tissue 
culture plates, 5,000 cells per well with 250 L medium. After 72 hrs, the medium 
was removed and Cell Titer 96 Aqueous One solution (Promega Co., Madison, WI) 
was added to each well. The viability of cells was measured by using a SpectraMax 
plate reader (Molecular Devices, Inc. Sunnyvale, CA) at 490 nm. Relative viability 
was calculated with cells treated only with medium alone as a control.  
 
RESULTS  
Liposome composition and characterization 
The main goal of our investigation is to demonstrate that pHLIP can promote cellular 
uptake of PEGylated liposomes and enhance lipid mixing and fusion between 
liposomal and cellular membranes. It is well established that PE lipids (such as 
DOPE), which are minimally hydrated and have small headgroups, possess high 
fusogenic propensity [24]. In our study, we tested both fusogenic (DOPE-based) and 
non-fusogenic (DOPC-based) liposomes.  
 
To introduce pHLIP in a liposome coat, we conjugated DSPE-PEG2000 maleimide lipid 
with Cys residue in the N-terminal region of pHLIP. Due to the fact that pHLIP is an 
unstructured polypeptide, it could be dissolved in organic solvent with no harm to its 
structure. The conjugation product was characterized by SELDI-TOF mass 
spectrometry (Figure 1). The narrow peak at 4154 Da corresponds to pHLIP, and the 
broad peak centered at ~7000 Da corresponds to the conjugation product DSPE-
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PEG2000-pHLIP. DSPE-PEG2000-pHLIP was used for preparation of liposomes 
containing pHLIP. The detailed composition of liposomes used in the study is given in 
Table 1. The first number in the formulation code refers to the mole percentage of 
pHLIP-PEG lipids (DSPE-PEG2000-pHLIP), whereas the second number refers to the 
amount of PEG lipids (DSPE-PEG2000). The different formulations of liposomes were 
characterized by cryo-TEM and DLS. Special attention was given to the stability of 
DOPC/DOPE ‘5:5’ and ‘10:0’ formulations containing 5% and 10% DSPE-PEG2000-
pHLIP, respectively. The average size of DOPC and DOPE liposomes of ‘5:5’ 
formulation was about 125 nm in diameter with PDI (polydispersity index) of about 
0.06 and Zeta potential of about -16 mV. The measurements were performed within 
several days after liposomes preparations and numbers represent averaged values. The 
average size of DOPE and DOPC liposomes containing 10% DSPE-PEG2000-pHLIP 
was larger in size. The DOPE liposomes were stable for several days with average size 
of 150 nm, PDI of 0.06 and Zeta-potential of -19.5 mV. However, the DOPC ‘10:0’ 
liposome formulation was very unstable with increased size of liposomes of 200 nm.  
Figure 2 shows cryo-TEM images of DOPC/DOPE liposomes with and without 
pHLIP in liposome coat. These liposomes have formulations “0:10” (an example of a 
control liposome without pHLIP) and “5:5” (an example of a pHLIP-containing 
liposome) (Table 1). The TEM images illustrate that our liposome samples consist of a 
mixture of small unilamellar (<100 nm) and multilamellar vesicles, mostly with two 
bilayers (~100 nm). pHLIP-containing liposomes show more complex multilamellar 
structures, especially for liposomes consisting of fusogenic DOPE lipids (Figure 2B), 
which is most probably due to the pHLIP-induced membrane fusion. Since pHLIP has 
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high affinity to the lipid bilayer of membrane, fusion promoted by pHLIP results in 
formation of multilamelar structures rather than bigger liposomes. Such multilamelar 
structures allow interaction of pHLIP peptides with lipid bilayer of the same liposome. 
 
Inter-liposomal fusion  
First, we investigated pHLIP-induced membrane fusion on the model system of 
phospholipid vesicles. Inter-liposomal fusion was monitored by fluorescence increase 
of octadecyl rhodamine B (R18), which was part of liposome composition. When 
rhodamine dye molecules are in close proximity to each other, such as in the case of 
high concentration (7 mol % of R18) in two-dimensional membrane space, the self-
quenching occurs [25]. The fluorescence increase is observed when liposomes 
containing R18 fuse with unlabeled POPC liposomes, which leads to the decrease of 
effective concentration of R18, that is, an increase of averaged distance between 
rhodamine dyes. Four types of R18-labeled liposomes were studied, i.e. DOPC- or 
DOPE-based PEG-liposomes with or without pHLIP (Figure 3).  
 
Typical changes of R18 fluorescence are shown in Figure 3A. The fluorescence signal 
of solution containing unlabeled POPC liposomes (6 mM) mixed with an equal 
volume of R18-labeled liposomes (200 μM) at pH 8 was taken as 0% of fusion. After 
equilibrating at pH 8 for ~ 2 min, the pH was dropped from 8 to 4, and increase of 
fluorescence indicating on fusion was observed only for liposomes containing pHLIP 
in coat. Non-physiological pH 8 and pH 4 in this model assay on liposomes were used 
to ensure that all pHLIP molecules exist in either state II or state III, respectively. 
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Fluorescence signal measured after 5 freeze-thaw cycles was taken as 100% of fusion. 
Furthermore, we investigated dependence of fluorescence increase on amount of 
unlabeled POPC liposomes (Figure 3B). Mixing of R18-liposomes containing pHLIP 
with increasing concentrations of unlabeled POPC liposomes led to the enhancement 
of de-quenching, indicating that more inter-liposomal fusion had occurred. On the 
contrary, control liposomes (without pHLIP) showed no fluorescence change as the 
concentration of unlabeled POPC increased. Thus, inter-liposomal fusion is strongly 
dependent on the presence of pHLIP. 
 
To confirm that increase of R18 fluorescence is associated with fusion, not just flip-
flopping of R18 we performed another fusion assay. 50 nm DOPC liposomes of ‘5:5’ 
formulation encapsulated with fluorescent dye ANTS were mixed with 200 nm POPC 
liposomes encapsulated with DPX, quencher of ANTS fluorescence. The fluorescence 
signal of ANTS was decreased only when pH was reduced from 8 to 4 (Figure 3C). 
The decrease of ANTS emission could occur only in the result of fusion of liposomes 
and mixing of ANTS with DPX.   
 
pHLIP-mediated inter-liposomal association (‘sticking’) takes place at pH 8, since 
binding of pHLIP to lipid bilayer at pH8 (without insertion into membrane) is 
associated with energy release of about 6 kcal/mol [23]. At the end of the equilibration 
period of 2 min at pH 8, most of pHLIP peptides could be associated with an inter-
liposomal POPC membrane, and the subsequent pH drop triggers membrane fusion, 
since pHLIP inserts into bilayer and adopts TM configuration within about 60 sec after 
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changes of pH [22].  The peptide inserted state is stabilized by release of additional 2 
kcal/mol of energy [23]. Our data indicate that most of pHLIPs prefer the inter-
liposomal POPC membrane surface over its own intra-liposomal DOPE or DOPC 
surface, which is perhaps because adequate level of PEGylation effectively shields the 
intra-liposomal membrane from association with pHLIP. However, we cannot exclude 
that some amount of peptides inserts in membranes of their own liposomes as well. 
 
The effect of PEGylation level (1-10 mol %), pHLIP content (1-10 mol %), and 
liposome type (DOPC vs. DOPE) on the efficiency of inter-liposomal fusion was 
further investigated (Figure 3D). We established that 5 mol % of PEG2000 is an optimal 
level of PEGylation. This level of PEGylation roughly corresponds to the transition 
between the tight packing ‘brush’ conformation and the loose ‘mushroom’ 
conformation of the liposomal PEG shield [26]. A lower level of PEGylation at 1 mol 
% led to the reduction of fusion for both DOPC and DOPE pHLIP-liposomes. In this 
case, we suspect that the membrane surface is not adequately shielded by PEG and too 
many pHLIP molecules associate and insert into the intra-liposomal DOPC/DOPE 
membrane at pH 8 and 4, respectively. However, more PEGylation at 10 mol % also 
led to lesser inter-liposomal fusion, especially for DOPC pHLIP-liposomes, perhaps 
because shielding of the DOPC surface is too complete and membrane fusion becomes 
difficult. At 10 mol % PEGylation, DOPE-based liposomes show higher percentage of 
fusion than DOPC-based liposomes (35% vs. 12%), in agreement with the fusogenic 
nature of PE lipids. However, when the amount of PEGylation is reduced to 5 mol %, 
DOPC-based pHLIP-liposomes are just as adapt at membrane fusion as DOPE-based 
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liposomes. Given the same overall amount of PEGylated lipids, (1, 5, or 10 mol %), 
the presence of more pHLIP molecules always correlate with higher levels of 
membrane fusion, except of DOPC liposomes containing 10% of PEG-pHLIP 
(compare to DOPC liposomes containing just 5% of PEG-pHLIP), which most 
probably is associated with pure stability of this particular formulation. Therefore all 
experiments on cells were performed with liposomes containing no more than 5% of 
PEG-pHLIP. 
 
Cellular uptake of liposomes 
Cellular toxicity of liposomes with (‘5:5’) or without (‘0:10’) pHLIP was tested on 
A549 cells at both pH 6.2 and pH 7.4. Cells were treated with increasing 
concentrations of liposomes (up to 400 µM of lipids) for 1 and 2 days followed by 
standard MTS assay to check cells viability. No cellular toxicity was observed (data 
not shown). 
 
Membrane fusion between liposomes and cells was evaluated in a cell suspension 
assay. A549 cells in suspension were treated with fluorescently labeled pHLIP-
liposomes (“DOPE+pHLIP” or “DOPC+pHLIP”) or control-liposomes without pHLIP 
(“DOPE” or “DOPC”) under various conditions. After washing, fluorescence of 
individual cells was counted using a cellometer. The average fluorescence of ~ 2000 
treated cells was calculated and normalized to that of untreated cells.  First, we 
investigated whether pHLIP can induce membrane fusion between liposomes and cells 
in a pH-dependent fashion. A549 cells were treated with R18-labled DOPC or DOPE 
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liposomes with or without pHLIP at pH 7.4 or 6.5. Incubation with cells was either 15 
min in PBS (Figure 4A) or 60 min in serum-free DMEM (Figure 4B). For DOPC 
liposomes at pH 7.4, no difference in fluorescence intensity was observed between 
cells treated with pHLIP-liposomes vs. cells treated with control liposomes. However, 
at pH 6.5, the presence of pHLIP increased the amount of lipid mixing between 
liposomes and cells. The difference in cellular uptake of DOPE-based liposomes with 
and without pHLIP was observed already at pH 7.4, while the effect became more 
pronounced at pH 6.5. The results support the idea that pHLIP insertion into cellular 
membrane at low pH can facilitate uptake of liposomes by cells. Due to the fusogenic 
nature of DOPE lipids, DOPE-based liposomes show much higher cellular uptake than 
DOPC-based liposomes in general, which is in agreement with the data of inter-
liposomal fusion assay discussed previously. The different incubation time of 15 min 
vs. 60 min might reflect different pathways of liposome-cell interaction. During short 
incubation period, predominantly direct liposomal fusion with plasma membrane 
occurs; while during long incubation period,  both fusion and cellular internalization 
through endocytosis (most probably, macropinocytosis) could happen. Our data show 
that the fluorescence signal is significantly higher at the longer incubation time, 
especially at low pH, suggesting that endocytosis plays an important role in pHLIP-
mediated cellular uptake of liposomes.  
 
Next, cell treatment was carried out at low temperature or in an ATP-depletion 
medium to reduce energy dependent endocytic uptake. The decrease of temperature 
significantly (~ 80%) reduced overall liposome uptake (Figure 4C). Regardless of the 
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route of entry (being endocytosis or direct interaction with plasma membrane), first, 
pHLIP needs to insert into the cellular membrane in an environment of low pH. Our 
kinetics studies indicate that the rate of insertion is reduced with decrease of 
temperature [22]. Therefore, we assume that experiments at low temperature would 
affect both fusion, and endocytotic pathways of liposomal uptake. Results from the 
experiments of cells treated at pH 6.5 for 60 min in the ATP depletion medium or 
serum-free DMEM (Figure 4D), indicate that endocytosis is responsible for ~ 50% of 
pHLIP-mediated cellular uptake of liposomes. 
 
How does the amount of pHLIP and PEG present on liposome coat influence the level 
of cellular uptake of liposomes? To investigate this question, cells were incubated with 
DOPC-liposomes of various compositions in serum-free DMEM at pH 6.5 for 60 min. 
When the total amount of PEG-lipids was held constant, the presence of more pHLIP 
led to higher cellular uptake (Figure 4E, dark grey bars within the 10 mol % total 
PEG-lipid series). Furthermore, less amount of PEGylation was more favorable for 
membrane fusion, resulting in higher cellular uptake (Figure 4E, 1 mol % vs. 10 mol 
%). The results are consistent with the data obtained in inter-liposomal fusion assay. 
 
The uptake of liposomes was assessed using the fluorescence of Rho-FA (R18). In 
place of R18, we also incorporated rhodamine-PE or fluorescein-DHPE into the 
liposomes as alternative fluorescent probes. Cells were incubated with DOPC-
liposomes with or without pHLIP in serum-free DMEM at pH 6.5 for 60 min. A 
similar pattern of pHLIP-dependent cellular uptake of liposomes was observed 
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regardless of fluorescent lipid probe used (Figure 4F). Therefore, pH- and pHLIP-
dependent cellular uptake of liposomes is not influenced by the choice of the 
fluorescent lipid. 
 
Fluorescence microscopy 
Fluorescent lipids incorporated in liposomes allow visualization of liposome-cell 
interactions using fluorescence microscopy. A549 cells in suspension were incubated 
with DOPE liposomes with or without pHLIP in serum-free DMEM medium at pH 6.5 
for 1 hr. After washing, treated cells were grown on collagen-coated dishes and 
became adherent. The light (Figure 5A-a, -c) and fluorescent images (Figure 5A-b, -d) 
were taken 4 days after cell treatment with liposomes. Cells treated with pHLIP-
containing liposomes show much stronger fluorescence than cells treated with 
liposomes containing no pHLIP. It is evident that R18 of liposomes containing pHLIP 
targeted specific cellular compartment. To figure out what organelle was marked by 
R18 fluorescence, cells treated with pHLIP-liposomes containing R18 (Figure 5B-b) 
were labeled with Mito-tracker and ER-tracker to stain mitochondria (Figure 5B-a) 
and endoplasmic reticulum (data not shown), respectively. The co-localization study 
reveals that the R18 (Figure 5B-b) was co-localized in mitochondria (Figure 5B-c, 5B-
d). R18 contains a hydrophobic lipid tail and rhodamine ester, which is positively 
charged at physiological pH. It is well known that such amphiphilic molecules 
specifically target mitochondria in living cells [27-30]. It is important to outline that 
effective mitochondria targeting by R18 was observed mostly in case of pHLIP-
mediated uptake of liposomes by cells. 
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Liposomes containing a different rhodamine lipid probe, Rhod-PE, were also 
investigated. In this case, the rhodamine portion of the molecule is zwitterionic and 
neutral, (while the overall molecule is -1 negatively charged due to the phosphate 
anion in the lipid headgroup). Adherent A549 cells were incubated with Rhod-PE 
labeled liposomes with or without pHLIP in PBS at pH 6.3 for 30 min, and 
distribution of fluorescent signal was monitored under microscope immediately after 
cell washing. Compared to cells treated with control liposomes without pHLIP (Figure 
5C-b), cells treated with pHLIP-containing liposomes (Figure 5C-d) were more 
fluorescent and have different distribution of fluorescent signals. Unlike R18, Rhod-
PE lipids do not stain mitochondria, but instead accumulate in perinuclear region and 
plasma membranes (Figure 5C-d). By contrast, punctate staining was observed for 
cells treated with liposomes without pHLIP (Figure 5C-b), indicating endosomal 
trapping of liposomes. 
 
In addition, liposomes containing fluorescein-DHPE probes (5 mol %) were also 
tested. Adherent A549 cells were treated with fluorescein-labeled pHLIP-containing 
DOPC liposomes in PBS, pH 6.2, for 1 hr (Figure 5D-a) and the same cells were 
stained with wheat germ agglutinin conjugated with Texas Red to visualize plasma 
membrane (Figure 5D-b). It is clearly seen that the plasma membrane of cells treated 
with pHLIP-containing liposomes was stained with fluorescein lipids, revealing that 
pHLIP induced fusion between liposome and plasma membrane. 
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Finally, instead of fluorescent probes, nanogold particles (1.4 nm) conjugated to fatty 
acid, were introduced in liposome coat. Adherent A549 cells were treated with 
nanogold-containing DOPE liposomes with or without pHLIP in serum-free DMEM at 
pH 6.5, for 15 min, followed by fixation and silver enhancement to enlarge nanogold 
particles up to micron size particles and visualize them under light microscope. 
Liposomes containing pHLIP delivered more nanogold to cells (Figure 5E-b) than 
liposomes without pHLIP (Figure 6E-a). Similar to the localization of Rhod-PE probe, 
nanogold particles are clearly visible at perinuclear region and plasma membranes of 
treated cells. 
 
Delivery of an encapsulated cargo 
The main goal in effective use of liposomes, as a delivery agent, is to deliver and 
release polar payload into cells. Therefore, we investigated pHLIP-mediated liposomal 
delivery of an encapsulated cargo. Propidium iodide (PI), a membrane-impermeable 
DNA staining dye, was encapsulated in liposomes to serve as the model payload. 
Adherent A549 cells were incubated in serum free DMEM at pH 6.5, for 1 hr with 
fluorescein-labeled DOPE liposomes loaded with PI, with or without pHLIP in 
liposomal coating (Figure 6). Fluorescein (Figure 6A-B) and PI (Figure 6C-D) 
fluorescent images, taken after 1 hour treatment, evidently demonstrate that pHLIP-
containing liposomes delivered much more PI to the nuclei than control liposomes. 
Further, more staining of cellular membranes was observed on cells treated with 
pHLIP-containing liposomes. According to the data presented on Figure 4, 
endocytosis is responsible only for ~ 50% of the pHLIP-mediated cellular uptake of 
70 
 
liposomes and the other 50% are due to the pHLIP-induced direct fusion with plasma 
membrane (Figure 4D). Fusion is much faster than endocytosis. Our study shows that 
the internalization of liposomes was observed even after 15 min treatment (Figure 4). 
Thus, we assume that the release of PI encapsulated in liposomes occurred as a result 
of fusion of liposomes with plasma membrane. These results are consistent with the 
notion that pHLIP can promote membrane fusion and lipids exchange, leading to 
enhancement of payload release.  
 
Delivery of liposomal ceramide inhibites proliferation of cancer cells 
Our data suggest that pHLIP can enhance cellular delivery of liposomes. Can this 
approach be applied toward the delivery of cytotoxic agents of therapeutic potential? It 
was demonstrated that PEGylated liposomes containing short chain C6 ceramide can 
induce apoptosis in human breast cancer cells [31-33]. We prepared pHLIP-containing 
liposomes with 30 mol % of C6 ceramide to investigate whether pHLIP can enhance 
the cellular delivery of this cytotoxic signaling lipid. Cryo-TEM images confirmed the 
integrity of the ceramide- and pHLIP-containing liposomes (Figure 7A, B). The size 
of the liposomes were measured immediately after extrusion (Figure 7C) and then 
monitored for 3 days (Figure 7D). Ceramide-containing liposomes with pHLIP were 
slightly larger (~ 125 nm in diameter) than liposomes without pHLIP (~ 95 nm in 
diameter). Nonetheless, aggregation of pHLIP-containing liposomes was not 
significant during the 3-day follow-up period. These data confirmed that the ceramide 
liposomes were uniform in size and stable in solution.  
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The cytotoxic effects of ceramide-containing liposomes were evaluated in anti-
proliferation assay. First, A549 cells in suspension were incubated with ceramide-
liposomes with or without pHLIP, at pH 8.0, or pH 6.1, for 60 min in a phosphate 
buffer. pH 8 was used to enhance pH-dependent effect of pHLIP-coated liposomes. 
After washing, treated cells were grown on 96-well plates (at ~ 5000 cells per well) 
for 3 days before viable cell populations were counted by MTS colorimetric assay. 
When the liposome treatment was carried out at pH 8, control liposomes exhibit some 
toxicity to the cells, while pHLIP-coated liposomes show practically no toxicity 
(Figure 7F). By contrast, when the treatment was carried out at pH 6.1, significant 
differences in cell viability was observed between cells treated with pHLIP- and 
ceramide-containing liposomes (< 10% of cell survival), and cells treated with control 
liposomes containing ceramide, but no pHLIP (~ 60% of cell survival) (Figure 7E). 
Compared to untreated cell population, the treatment with ceramide-containing 
liposomes at low pH alone inhibited <40% of cell proliferation, whereas the presence 
of pHLIP in liposome coat contributed to an additional 50% of inhibition, presumably 
by elevating the intracellular concentration of C6 ceramide. Thus, pHLIP enhances 
delivery of liposomal ceramide to cells at low pH, which induces cell death.  
DISCUSSION 
pH-sensitive liposomes were designed to mimic the highly efficient intracellular 
delivery systems utilized by viruses and pathogenic organisms. There are two main 
pathways of viruses entry into cells: direct fusion with plasma membrane and 
endocytotic uptake by host cells [34-41]. Membrane fusion also occurs in  membrane 
trafficking, including neurotransmitter release in synaptic transmission, gamete 
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formation in sexual reproduction, and myotube formation in organ development [42]. 
In all these cases, two distinct membranes have to come close to each other, merge, 
mix, which leads to the fusion. This process is triggered and regulated by fusion 
proteins. The entire fusion machinery of viruses is a single fusion protein within their 
own membrane, while intracellular fusion machines consist of several proteins located 
in both membranes to be fused. Despite the differences between viral and intracellular 
fusion proteins, their main role is to bring two individual membranes together [34, 37, 
42-45]. Only upon activation, often by low pH in endosomes, does the fusion peptides 
(which are a part of the fusion protein) become exposed and available for insertion 
into the target membrane [42]. The process of membrane fusion mediated by fusion 
proteins can be as fast as 8 ms [46]. 
 
Inspired by the action of fusion peptides, which insert into the target membrane to 
induce fusion, we decorated PEG-coated liposomes with pHLIP (Figure 8A). Our data 
indicate that pHLIP adopts random coil configuration in aqueous solution at normal 
and high pH [21]. We assume that on the surface of liposomes coated with PEG 
polymer, pHLIP would adopt coil configuration as well. Our estimation of volume 
occupied by single pHLIP coil according to the freely-jointed model of polymer 
physics and the surface area on the liposomes available for the coating indicates that 
about 50% of liposome surface is coated with pHLIP peptides in the case of ‘5:5’ 
liposome formulation. At pH<7.0 Asp/Glu residues are protonated, which increases 
peptide hydrophobicity and affinity to membrane and leads to the peptide insertion 
into lipid bilayer and formation of a stable transmembrane helix. The biophysical 
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studies indicate that process on model membrane could be completed within 60 sec 
[47]. Our biophysical inter-liposomal assays clearly demonstrates that indeed pHLIP 
induces fusion of both fusogenic (DOPE-based) and non-fusogenic (DOPC-based) 
PEG-liposomes with POPC vesicles at low pH. The content of liposomes is mixing in 
a result of the fusion. Experiments on cultured cells further confirmed pHLIP’s ability 
to induce fusion and lipid mixing between PEG-liposomes and biological membranes, 
evidenced by the following:  i) pHLIP-induced  cellular uptake of DOPE- and DOPC-
based PEG-liposomes are dependent on acidic extracellular pH, and ii) fluorescent 
lipid probes (or nanogold-lipid conjugates) brought in by the liposomes are distributed 
throughout the cell. It is important that lipid mixing occurs not in a result of flip-
flopping of fluorescent lipids and fatty acids, but in a result of membrane fusion, 
which leads to the efficient cytoplasmic delivery of liposomal payload. In addition to 
delivering probes and model cargos we also showed that, at low extracellular pH (pH 
6.0), pHLIP can enhance the biological effect of PEGylated liposomes containing 
short chain C6 ceramide, which induces apoptosis and cell death [48, 49]. We 
concluded that the presence of up to 5 mol % of PEG polymer in the liposomal 
coatings favors pHLIP interaction with the inter-membrane surface over its own intra-
liposomal surface. The amount of pHLIP peptide in the liposome coat correlates with 
the degree of fusion:  the more pHLIP, the more fusion.  
 
Our data indicate that there might be several routes of liposome entry into the cell: i) 
direct fusion with plasma membrane, and ii) endocytotic uptake of liposomes, and 
then, fusion with endosomal membrane (Figure 8B). In both cases, the first event is 
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the insertion of pHLIP peptides into target membrane triggered by reduced pH, 
bringing liposomal and cellular membranes close to each other, which can induce 
fusion of liposome with cellular membrane. Since there are many pHLIP peptides on a 
liposome surface, their simultaneous insertion might lead to plasma membrane raffling 
and blebbing, which may trigger internalization of liposomes. It is well documented 
that pHLIP shows direct spontaneous insertion into membrane of liposomes and cells 
in vitro and in vivo, and this process does not involve receptor interaction  [19, 50, 51]. 
Therefore, we assume that plasma membrane raffling and blebbing might promote 
macropinocytosis, which is an endocytic route of cellular internalization not associated 
with the activation of a particular receptor on the cellular surface [52-54]. More 
detailed investigation is needed to confirm that pHLIP-triggered endocytotic uptake of 
liposomes occur via macropinocytosis. When endosomes with encapsulated liposomes 
detach from the plasma membrane inside a cell, they undergo acidification. Low pH 
(5.0-5.5) inside endosomes would promote even more efficient insertion of pHLIP into 
the endosomal membrane, leading to lipid mixing and fusion. As a result, liposomal 
payload is released into the cytoplasm and liposomal lipids could be found in the 
membrane of various cellular compartments.  
pHLIP-coated liposomes represent a novel type of pH-sensitive “fusogenic” 
liposomes. In pHLIP-coated liposomes, the fusogenic properties are determined not 
only by the choice of lipids, but also by the presence of membrane-inserting peptides 
on the liposome surface, as in some pathogens. The energy of membrane-associated 
folding of pHLIP is utilized to bring liposomal and cellular membranes close to each 
other to induce lipid mixing, or membrane blebbing and raffling. Since extracellular 
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acidity is associated with the development of various pathological states, such as solid 
tumors, ischemic stroke, neurotrauma, epileptic seizure, inflammation, infection, 
wounds, cystic fibrosis, and others, pHLIP-coated liposomes could be used to deliver 
and release various diagnostic and therapeutic agents to these sites of disease. 
 
CONCLUSIONS 
We introduced new formulation of pHLIP-PEG-coated liposomes. pHLIP promotes 
cellular uptake of both fusogenic (DOPE-based) and non-fusogenic (DOPC-based) 
liposomes at low pH. Our data indicate that about 50% of cellular uptake of pHLIP-
PEG-coated liposomes at low pH could be attributed to the direct fusion with plasma 
membrane and about 50% due to the endocytotic pathway of cellular entry. Lipids and 
fatty acids conjugated with various reporters (such as fluorescent dyes or gold 
nanoparticles), when incorporated  into pHLIP-PEG-coated liposomes,  were 
distributed to various cellular compartments, including  mitochondrial, nuclear, and 
plasma membranes, at the same time, encapsulated in liposome polar cargo, such as 
propidium iodide, was delivered  to nuclear DNA  at low pH. We show that pHLIP-
PEG-coated liposomes containing C6-ceramide induced cell death much more 
effectively (~90% inhibition) than PEG-liposomes containing no pHLIP in their 
coating (~40% inhibition) at low pH. Since low extracellular pH is a characteristic 
feature of many pathological states, we assume that pHLIP-PEG-coated liposomes 
could be used for selective delivery and cytoplasmic release of diagnostic and 
therapeutic agents. 
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FIGURES 
 
 
 
 
 
 
Figure 1.  SELDI-TOF mass spectrum of DSPE-PEG2000-pHLIP. The narrow peak 
at 4154 corresponds to the pHLIP peptide. The broad peak centered at ~7000 Da 
corresponds to the conjugated product DSPE-PEG2000-pHLIP. The individual spikes 
on the broad peak differ from each other by the repeating unit(s) of PEG (mass: 44 
Da). The marked mass at 7029 corresponds to the expected mass of the product minus 
one unit of PEG (7074 – 44 = 7030 Da). 
  
85 
 
 
 
 
 
Figure 2. Cryo-TEM images of R18-labeled liposomes. The control liposomes 
without pHLIP are shown on panels (A) (DOPE/DSPE-PEG2000/R18, 83:10:7) and (C) 
(DOPC/DSPE-PEG2000/R18, 83:10:7); and the pHLIP coated liposomes are shown on 
panels (B) (DOPE/DSPE-PEG2000/DSPE-PEG2000-pHLIP/R18, 83:5:5:7) and (D) 
(DOPC/DSPE-PEG2000/DSPE-PEG2000-pHLIP/R18, 83:5:5:7). The images were 
obtained using JEOL 2100 TEM with an accelerating voltage of 200 kV. The total 
lipid concentration of samples shown is 1 mM. 
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Figure 3. Inter-liposomal fusion assays. (A) Increase of rhodamine fluorescence 
reflects fusion of membranes. The fluorescence changes were monitored in the 
solution of R18-labled DOPC or DOPE liposomes with or without pHLIP in liposome 
coat (200 µM total lipid concentration) mixed with equal volume of 6 mM POPC at 
pH 8. The addition of POPC liposomes to the solution of R18-labeled DOPC or DOPE 
liposomes at pH 8 leads to the fluorescence decrease due to the dilution (data not 
shown). Spectral signal at pH 8 was taken as “0% fusion,” the fluorescence was 
monitored several minutes after pH drop to pH 4, followed by 5 freeze-thaw cycles 
performed to induce complete fusion (“100% fusion”). Liposome formulations are 
‘5:0’ (with pHLIP) and ‘0:5’ (without pHLIP). (B) Dependence of fluorescence 
intensity changes of rhodamine on concentration of POPC liposomes when mixed with 
200 µM (total lipid concentration) of R18-labled DOPC or DOPE liposomes with or 
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without pHLIP in liposome coat. Liposome formulations are ‘10:0’ (with pHLIP) and 
‘0:10’ (without pHLIP). (C) To confirm that increase of rhodamine fluorescence 
occurs due to fusion of liposomes, another assay was carried. 50 nm DOPC liposomes 
of ‘5:5’ formulation with entrapped ANTS at pH 8 were mixed with 200 nm POPC 
with entrapped DPX, a quencher of ANTS fluorescence. The DOPC liposomes also 
contained 5% of R18. The increase of rhodamine fluorescence in a result of pH drop 
from pH 8 to pH 4 (red line) was accompanied by the decrease of ANTS fluorescence 
(black line) in a result of liposomes fusion and mixing of ANTS and DPX. (D) The 
efficiency of pHLIP-mediated inter-liposomal fusion depends on the amount of 
PEGylated lipids (with 5 mol % of PEG-lipids as the optimal). The detailed 
formulation of liposome composition is presented in Table 1. 
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Figure 4. Cellular uptake of liposomes. A549 cells in suspension were treated with 
fluorescently labeled liposomes (DOPC or DOPE) with or without pHLIP in liposome 
coat under various conditions. Cellular uptake of fluorescent liposomes was assessed 
by counting of fluorescent cells on a cellometer. All data were normalized to the 
fluorescence intensity of untreated cells (dotted line). (A-B) pH- and pHLIP-
dependent cellular uptake of liposomes is shown. Cells were incubated with R18-
labeled liposomes with (‘5:5’) or without (‘0:10’) pHLIP in liposome coat at pH 7.4 or 
6.5 in PBS for 15 min (A) or in serum-free DMEM for 60 min (B). (C-D) Cells were 
incubated with R-18 labeled liposomes at pH 6.5 in PBS at 4°C or 37°C for 15 min 
(C) and in serum-free DMEM or ATP depletion medium at 37°C for 60 min (D). Low 
temperature and ATP depletion medium are used to reduce endocytotic uptake. (E) 
Cellular uptake of DOPC liposomes (pH 6.5, DMEM, 37°C, 60 min) depends on 
amount of pHLIP and PEG in liposome coat. (F) The pH- and pHLIP-dependent 
cellular uptake does not depend on choice of fluorescent lipids. Liposomes (‘5:5’ 
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DOPC) containing different fluorescent lipids—Rho-FA (R18), Rhodamine-PE (Rho-
lipid), or Fluorescein-DHPE (FITC-lipid)—were incubated with cells (pH 6.5, 
DMEM, 37°C, 60 min), and pHLIP-dependent fluorescence increase was observed in 
each case. 
 
 
Figure 5. Cellular localization of liposomes. (A) A549 cells in suspension were 
incubated with R18 DOPE liposomes with (c & d: ‘5:5’) or without pHLIP (a & b: 
‘0:10’) in liposome coat in serum-free DMEM medium at pH 6.5 for 1 hr. The light (a, 
c) and fluorescent images (b, d) were taken 4 days after cell treatment with liposomes. 
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(B) Mito-tracker fluorescent dye was used to stain mitochondria of cells treated with 
R18 DOPE liposomes containing pHLIP (a). pHLIP mediated uptake of R18 
liposomes show specific staining of mitochondria (b).  An overlay of (a) & (b) is 
shown in panel (c) to be certain that the staining pattern of R18 is truly due to 
mitochondrial localization. On the panel (d) a zoom-in picture of mitochondria stained 
with R18 liposome is shown. (C) Adherent A549 cells were treated with Rho-PE 
DOPE liposomes with (c & d: ‘5:5’ formulation) or without pHLIP (a & b: ‘0:10’) in 
PBS at pH 6.3 for 30 min. Both light (a, c) and fluorescent images (b, d) were taken 
immediately after washing. (D) Adherent A549 cells were treated with fluorescein 
DOPC liposomes with 5 mol % of pHLIP-PEG-lipids (PBS, pH 6.2, 1 hr). Staining of 
plasma membrane by FITC-lipids of liposomes shown on panel (a) is confirmed by 
staining of the plasma membrane of the same cells by Texas Red-labeled wheat germ 
agglutinin, as shown on panel (b). (E) Adherent A549 cells were treated with 
nanogold-containing DOPE liposomes with or without pHLIP in serum-free DMEM 
(pH 6.5, 15 min). After fixation and silver enhancement, cells were visualized under 
the light microscope (a: no pHLIP; b: with pHLIP). Liposomes containing 10 mol % 
of pHLIP delivered more nanogold to cells (image b) than control liposomes without 
pHLIP (image a). The scale bar is 20 µm in all images. 
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Figure 6. pHLIP-mediated liposomal delivery of propidium iodide (PI). Adherent 
A549 cells were incubated in serum free DMEM (pH 6.5, 1 hr) with fluorescein-
labeled DOPE liposomes loaded with PI, with or without pHLIP (‘5:5’ or ‘0:10’ 
formulation) in liposomal coating. Fluorescent images of cells treated with pHLIP-
containing liposomes (A & C) or control liposomes without pHLIP (B & D) are 
shown side by side. The fluorescent images of the same cells were taken with two 
filter settings: green - fluorescein fluorescence; red - PI fluorescence. The exposure 
time is 172 ms for A & B and 80 ms for C & D. The scale bar is 20 µm. 
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Figure 7. pHLIP-mediated delivery of liposomal ceramide inhibits proliferation 
of cancer cells at low pH. (A-B) Liposomes containing 30 mol % of C-6 ceramide 
were characterized using Cryo-TEM: control liposomes without pHLIP and liposomes 
containing pHLIP are shown on panels A and B, respectively. (C) DLS was used to 
investigate the changes of liposome size with time. The size of the liposomes was 
measured immediately after liposome extrusion and monitored for 3 days. (D) A549 
cells in suspension were incubated with ceramide liposomes (with or without pHLIP) 
at pH 8.0 or 6.1 for 60 min in a phosphate buffer. After washing, treated cells were 
grown in 96-well plates for 3 days before viable cell populations were estimated via 
MTS assays. 
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Figure 8. Schematic presentation of pHLIP/PEG coated liposomes (A) and their 
interaction with cellular membranes (B). The encapsulated model payload 
molecules and the head-groups of fluorescent lipids are shown in red.  
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TABLES 
Formulations of fluorescently labeled liposomes  
 
Liposome code
a
 ‘0:10’ ‘1:9’ ‘5:5’ ‘10:0’ ‘0:5’ ‘1:4’ ‘5:0’ ‘0:1’   ‘1:0’ 
DOPC (or DOPE) 83%
b
 83% 83% 83% 88% 88% 88%  92%    92% 
DSPE-PEG2000-pHLIP 0% 1% 5% 10% 0% 1% 5% 0% 1% 
DSPE-PEG2000  10% 9% 5% 0% 5% 4% 0% 1% 0% 
Fluorescent lipids
c
 7% 7% 7% 7% 7% 7% 7% 7% 7% 
Formulations of nanogold labeled liposomes 
   Control-liposome  pHLIP-liposome  
DOPE    86%    86%  
DSPE-PEG2000   10%    0%  
DSPE-PEG2000-pHLIP  0%    10%  
Palmitoyl Nanogold  2.5%    2.5% 
R18    1.5%    1.5%  
Formulations of ceramide liposome 
  Control-liposome  pHLIP-liposome  
DOPC    37%    37% 
DOPE    17.5%    17.5%  
DSPE-PEG2000   7.5%    2.5%  
DSPE-PEG2000-pHLIP  0%    5%  
C8-PEG750 ceramide  7.5%    7.5% 
C6 ceramide   30%    30% 
R18    0.5%    0.5%  
Notes:  
a. Ratio in liposome code refers to molar ratio between pHLIP-PEG-lipids and 
PEG-lipids.  
b. Percentages indicate mole fractions.  
c. Fluorescent lipids are R18, Rho-PE, or fluorescein-DHPE.  
 
Table 1. Formulation of liposomes used in various experiments 
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ABSTRACT 
Progress in nanomedicine depends on the development of nanomaterials and targeted 
delivery methods. In this work, we describe a novel method for the preferential 
accumulation of gold nanoparticles in tumors. The method is based on the use of the 
pH (Low) Insertion Peptide (pHLIP

), which targets various imaging agents to acidic 
tumors. We compare tumor targeting by non-functionalized nanogold particles with 
nanogold-pHLIP conjugates, where nanogold is covalently attached to the N-terminus 
of pHLIP. We observed pH-dependent, pHLIP-mediated uptake of gold nanoparticles 
by cultured cells. Our most important finding is that intratumoral and intravenous 
administrations both demonstrated a significant enhancement of tumor uptake of gold 
nanoparticles conjugated with pHLIP. Statistically significant reduction of gold 
accumulation was observed in acidic tumors and kidney when pH-nonsensitive K-
pHLIP was used as a vehicle, suggesting an important role of pH in the pHLIP-
mediated targeting of gold nanoparticles. The pHLIP technology can substantially 
improve the delivery of gold nanoparticles to tumors by providing specificity of 
targeting, enhancing local concentration in tumors, and allowing staining throughout 
the entire tumor mass for an extended period of time (several days), which is 
beneficial for radiation oncology and imaging. The technology also could be applied 
to the delivery of other types of nanoparticles to diseased tissue.  
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INTRODUCTION 
Targeting of therapeutic nanoparticles could reduce side effects in treating cancer, as 
most antitumor drugs are toxic, killing not only tumor cells but also causing serious 
damage to healthy cells. One significant difference between cancerous and normal 
tissues is that the former exhibits a significantly acidic extracellular environment (1). 
Acidosis is a hallmark of tumor development both at very early and advanced stages 
(2, 3), as a consequence of anaerobic metabolism (the Pasteur effect) (4), the activity 
of carbonic anhydrases IX and XII (5), and the “aerobic glycolysis” known as the 
Warburg effect (6). Thus, the targeting of most solid tumors might be achieved by 
using pH-sensitive drugs and delivery systems. 
 
We have been developing a novel approach for targeting acidic tissue, which is based 
on the family of pH (Low) Insertion Peptides (pHLIPs). pHLIPs are water-soluble, 
moderately hydrophobic polypeptides originally derived from the bacteriorhodopsin C 
helix. A pHLIP is triggered by acidity to fold and insert across a membrane to form a 
stable transmembrane alpha helix (7). At neutral pH, pHLIP is in equilibrium between 
soluble and membrane-bound unstructured forms, while in a low pH environment, the 
protonation of negatively charged residues (Asp or Glu) (8, 9) enhances peptide 
hydrophobicity, increasing the affinity of the peptide for the lipid bilayer and 
triggering peptide folding and subsequent membrane insertion (8, 10). The Gibbs free 
energy of pHLIP binding to a POPC liposome surface at 37°C is about -7 kcal/mol 
near neutral pH and the additional free energy of folding and insertion across a lipid 
bilayer at low pH is nearly -2 kcal/mol (11). Thus the affinity of the peptide for a 
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membrane at low pH is several times higher than at neutral pH, allowing pHLIP to 
distinguish and mark acidic diseased tissue (8, 10, 12, 13). We show that the N-
terminus of pHLIP stays outside of the bilayer, while the C-terminus inserts across the 
lipid bilayer at low pH (14, 15), and small molecules (mostly imaging agents) 
covalently conjugated with the N-terminus of pHLIP can be delivered to tumors and 
tethered to the surfaces of cancer cells in a pH-dependent manner (12, 13, 16). As a 
control for pH-targeting in vivo we used K-pHLIP, where Asp residues in the 
transmembrane part of pHLIP were replaced by Lys residues. As a result, pHLIP loses 
its pH-dependent ability to insert into liposome phospholipid bilayers in vitro or cell 
membranes in vitro or in vivo (12, 13, 16). K-pHLIP labeled with fluorescent dyes, 
PET and SPECT agents show no targeting of tumors compared to the WT-pHLIP (12, 
13, 16, 17). pHLIP peptides conjugated with optical and PET imaging probes are 
listed as pH targeting agents in the Molecular Imaging and Contrast Agent Database 
(MICAD), NCBI. The results of the study demonstrating tumor targeting by SPECT-
pHLIP are currently in press (17). 
 
Davies et al. recently reported the pHLIP-mediated, pH-controlled delivery of 13 nm 
water soluble gold nanoparticles coated with luminescent europium into human 
platelets in vitro (18). In this related work, we show here that pHLIP not only induces 
the binding of 1.4 nm gold nanoparticles to cancer cells at acidic pH in vitro, but also 
that it stabilizes binding in tumors established in mice. Gold is an inert and non-toxic 
material with unique properties suitable for many applications such as cancer 
diagnosis and treatment (19-21). For example, the irradiation of gold atoms at their k-
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edge excitation energy (soft x-rays) will generate Auger electrons or highly reactive 
species that may produce a clinically achievable dose enhancement of as much as 10 
fold, capable of local inactivation of biological molecules (22, 23). The targeted 
delivery of gold to diseased tissue that we demonstrate here could lead to the 
successful application of gold nanoparticles in the diagnosis and treatment of tumors.  
 
RESULTS  
Biophysical studies 
Changes of tryptophan fluorescence and circular dichroism (CD) spectral signals can 
be used to monitor pHLIP binding to a membrane lipid bilayer at neutral pH and 
insertion at lower pH (7). We found that nanogold attached to pHLIP significantly 
quenches tryptophan fluorescence, making it unreliable for use in monitoring pHLIP 
insertion into a membrane (nevertheless, a wavelength shift of the tryptophan 
fluorescence maximum was observed. Since gold nanoparticles are achiral in the UV 
range (24) and do not interfere with the CD signals of a peptide, we measured the CD 
spectra of gold-pHLIP to study peptide-bilayer interactions. Our data indicate that 
pHLIP was predominantly unstructured at pH8 in the absence or presence of 
liposomes, whereas at low pH in the presence of POPC liposomes, we observed helix 
formation (Figure 1). Thus, we conclude that the attachment of gold nanoparticles to 
the N-terminus of pHLIP did not interfere with the ability of the peptide to form a 
helical structure interacting with the membrane at low pH.  We interpret these data to 
indicate that the pHLIP inserted into the membrane at low pH when it formed a helix. 
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Nanogold uptake by cultured cells 
We compared the binding of gold-pHLIP or gold nanoparticles to cultured cells at 
neutral and low pHs. Nanoparticles (2 μM, 200 μL) were incubated with HeLa-GFP 
cells at pH7.4 or 6.5. After 1 hour, cells were washed, fixed, and stained with silver 
enhancement solution, resulting in the deposition of silver on gold nanoparticles to 
form micrometer sized particles, which were visualized under a light microscope 
(Figure 2).  The images on Figure 2 were analyzed according to equation 2 (see 
Methods) to establish the ratios of gold (and silver) concentrations between the cells 
treated with gold-pHLIP or gold nanoparticles and the untreated cells at pH7.4 and 
6.5. Cells treated with gold-pHLIP nanoparticles at both pHs (Figure 2c, g) showed 
higher uptake of gold (3 fold at pH7.4 and 6.4 fold at pH6.5) compared to cells treated 
with unmodified gold nanoparticles (Figure 2b, f). Cellular uptake of gold-pHLIP 
nanoparticles at pH6.5 (Figure 2g, h) was 1.6 times higher than that at pH7.4 (Figure 
2c, d). These data demonstrated the pH-dependent, pHLIP mediated uptake of gold 
nanoparticles by cells. 
 
Animal studies 
When subcutaneous HeLa tumors reached 5-8 mm in diameter, they were 
intratumorally or intravenously (IV) injected with gold nanoparticles, gold-pHLIP, and 
gold-K-PHLIP conjugates. At 24 h after intratumoral administration of 15 μg gold or 
gold-pHLIP nanoparticles, mice were euthanized, and the tumors and major organs 
were harvested. The amount of gold in the tissues and organs was established by ICP-
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MS analysis (Figure 3a and Table 1 supporting information). These results indicated 
that up to 8 μg (i.e. 54% id/g) of gold per gram of tumor was delivered by pHLIP and 
remained in the tumor after 24 h, compared tp 0.7 μg/g (8% id/g) in the case of  non-
functionalized gold nanoparticles. Accumulation of gold was also observed in kidneys 
(about 2.1 μg per gram). Since small particles (1.4 nm) were used in this study, it is 
likely that clearance was predominantly urinary, as has been observed with 
fluorescent-, PET- and SPECT-labeled pHLIP constructs (13, 25). We have previously 
observed that the pHLIP can accumulate in kidneys due to the low pH in the tubules 
(16, 26). 
 
I.V. administration was given as two consecutive injections within 24 h. Split dosing 
was employed to avoid high-concentration mediated aggregation. Each injection 
contained 150 μL of 20 μM gold-pHLIP, gold-K-pHLIP, or non-functionalized gold 
particles (i.e. 45 μg). Necropsies were performed 24 h after the last injection. These 
data showed that 1.4 μg of gold per gram (1.5% id/g) of tissue was delivered by 
pHLIP to the tumors (Figure 3b and Table 1 supporting information). When pH-
nonsensitive K-pHLIP was used as a delivery vehicle, tumor targeting was reduced 3 
fold (0.47 μg/g or 0.5%). The uptake of gold-K-pHLIP was also reduced 3 fold in 
kidneys, and the distribution in other organs was similar to gold-pHLIP. 
 
To assess distribution of these gold nanoparticles within tissues, tumors, kidneys, and 
livers were collected and sectioned 4 h and 24 h after gold-pHLIP or gold nanoparticle 
administration. Silver enhancement was used to visualize the gold nanoparticles in 
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tissue sections. The same conditions of silver enhancement were used for all slides 
shown in Figure 4. The amount of gold/silver correlated with the darkness of the tissue 
sections. These data show that gold distribution within the tumors, kidney, and liver 
were higher and uniform at both time points for gold-pHLIP injection than for 
unmodified gold administration.  
 
The sections were further analyzed under a microscope with x10 (Figure 5) and x100 
(Figure 6) objectives. The gold distribution in tumors and livers (Figure 5d, l) was 
homogeneous, in contrast to the distribution in kidneys (Figure 5h), where the gold 
was mostly accumulated in the cortex. Cellular localization was confirmed by staining 
of cell nuclei with DAPI (Figure 6). The images of the tumor sections demonstrated 
that pHLIP was distributed throughout the entire tumor mass, penetrating to the cells 
in the tumor interior and labeling the extracellular space and cellular membrane 
(Figure 6a-c).  
 
DISCUSSION 
Gold nanoparticles are of interest as potential diagnostic and therapeutic agents in 
vivo, since they can be used as X-ray contrast agents (27), radiation enhancers (28), 
and laser (29, 30) and radiofrequency (31) thermotherapy enhancers. If tumors can be 
loaded with gold, this would lead to a higher dose to the cancerous tissue compared 
with the dose received by normal tissue during a radiotherapy treatment. Calculations 
indicate that the dose enhancement can be significant, as much as 200% or greater 
(28). Gold nanoparticles are not toxic: the LD50 of this material is approximately 3.2 g 
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Au kg
–1
 (27). Thus, the targeted delivery of gold nanoparticles could improve the 
treatment of cancers. Specific delivery can be accomplished by conjugating gold or 
any other nanoparticles to antibodies or ligands that target proteins overexpressed on 
cancer cell surfaces, and this approach has been actively explored for many years for 
delivery of small molecules. However, several recent studies have raised serious 
questions on the efficacy of targeting ligands on the nanoparticle accumulation in 
tumor tissues. Multiple reports have shown that targeted nanoparticles did not lead to 
increased tumor accumulation over non-targeted controls, although increased cellular 
uptake was observed in each case (32-34).  In addition, histological studies showed 
that antibodies conjugated with gold nanoparticles do not penetrate deeply into 
tumors, but mostly stain peripheral tumor regions (35). The direct injection of micron-
sized gold particles does not lead to tiumor targeting, as particles stayed only at the 
injection site and were not able to diffuse even within a tumor, hindering tumor 
coverage (22).  
 
In the present work, we report the promising finding that pHLIP shows pH-dependent 
uptake of small gold nanoparticles by cultured cells, and, the most important, pHLIP 
can enhance IV delivery of gold nanoparticles to tumors by 6 fold. On the other hand, 
nano-sized gold particles with no conjugated pHLIP were washed out quickly from 
tumors and other organs. Targeting with the pH-insensitive K-pHLIP (wherein two 
Asp residues were replaced by Lys) resulted in statistically significant 3 fold 
reductions of gold accumulation.  We interpret these data to indicated that the 
preferential distribution of pHLIP-targeted gold was mediated by the acidosis present 
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in tumors and kidney. The direct injection of gold-pHLIP into tumors resulted in 
nearly uniform labeling of cancer cells with gold nanoparticles throughout the entire 
tumor. Direct injection resulted in accumulation of 8.1 μg/g (54% id/g) in the tumor 
after 24 h. An N-fold increase in diameter gives N
3
 increase in number of gold atoms 
per particle, so with gold particles of 14 nm it might be possible to increase the 
amount of gold 1000-fold and to reach about 1% of gold of tumor mass, which is the 
amount that would be needed for a significant enhancement of the radiation 
therapeutic effect.  
 
This work demonstrated that pHLIP can mediate targeted delivery of nanoparticles to 
tumors. Further improvements of nanoparticle coatings may be able to improve 
bioavailability, enhance tumor targeting and reduce accumulation in non target organs, 
pHLIP technology can substantially improve the delivery of gold nanoparticles to 
primary tumors (and possibly metastatic lesions) by providing specificity of targeting, 
enhancing local concentrations, and improved retention in the tumor mass for an 
extended period of time (several days). 
 
METHODS  
Peptide conjugation with gold nanoparticles 
The pHLIP (ACEQNPIYWARYADWLFTTPLLLLDLALLVDADET) and K-pHLIP 
(ACEQNPIYWARYAKWLFTTPLLLLKLALLVDADET) peptides were prepared by 
Dr. James I. Elliott at the W.M. Keck Foundation Biotechnology Resources 
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Laboratory at Yale University (New Haven, CT). Monomaleimido Nanogold
®
 and 
non-functionalized particles (1.4 nm) were from Nanoprobes, Yaphank, NY. A pHLIP 
peptide containing a single cysteine residue near its N-terminus was conjugated with 
the single maleimide group on each nanogold particle. The progress of the coupling 
reaction was monitored by reversed phase HPLC. The concentration of peptide and 
nanogold was determined by absorbance at 280 nm (=13,940 M−1 cm−1) and 420 nm 
(=155,000 M−1 cm−1), respectively.   
 
Circular dichroism measurements 
Circular dichroism (CD) measurements were carried out on a MOS-450 spectrometer 
(BioLogic; Montrose, CO) at 25°C. Nonfunctionalized nanogold particles or 
nanogold-pHLIP conjugates were pre-incubated with 200 mol excess of POPC (1-
Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine from Avanti Polar Lipids, 
Alabaster, AL) liposomes in 20 mM phosphate buffer, pH8.0. Liposomes with 50 nm 
diameter were prepared by extrusion. To induce the folding/insertion of peptide into 
the membrane lipid bilayer, HCl was added to lower the pH value from 8 to 4. CD 
signals of gold nanoparticles were taken as baseline signals and were subtracted from 
the corresponding signals of the nanogold-pHLIP conjugates. 
 
Cell lines 
HeLa cells (human cervix adenocarcinoma, ATCC; Manassas, VA) without and with 
stable GFP expression, were cultured in Dulbecco’s Modified Eagle’s Medium 
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(DMEM) supplemented with 10% fetal bovine serum, 10 μg/mL of ciprofloxactin in a 
humidified atmosphere of 5% CO2 and 95% air at 37°C. Some cells were adapted by 
serial passages to improve growth in low pH medium (pH6.5). The pH 6.5 medium 
was prepared by mixing 13.5 g of dry DMEM with 0.2 g of sodium bicarbonate in 1 L 
of deionized water. 
 
Experiments on cultured cells 
HeLa-GFP cells grown in pH6.5 or 7.4 media were seeded in an 8-chamber slide 
(Lab-Tek
TM
, Thermo Scientific; Rochester, NY). At 80% confluency, cells were 
treated at pH 6.5 or 7.4 with 2 μM of nanogold or nanogold-pHLIP in 200 μL of 
serum-free DMEM at 37°C under 5% CO2. Cells not treated with nanogold were used 
as negative controls. After incubation for 1 h, the treatment solution was removed and 
cells were washed twice with serum-free DMEM (pH 7.4), and once with sterile PBS 
(pH7.4).  Subsequently, the cells were fixed with cold methanol at -20°C for 15 min, 
and then washed twice with sterile PBS (pH7.4) and once with deionized water. After 
air drying, the chamber walls were removed and the cell slides were developed with 
freshly prepared HQ SILVER™ reagent (Nanoprobes; Yaphank, NY). The reagent 
nucleates on the nanogold particles, resulting in the precipitation of metallic silver and 
the formation of micrometer sized particles with low background. The developing 
time was varied until optimal conditions were found (about 20 min). Subsequently, the 
cell slides were rinsed twice with deionized water, and viewed under a light 
microscope.  
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Estimation of cellular uptake of gold/silver based on the analysis of cell images  
After silver staining, the brightfield images of cells were analyzed with the ImageJ 
program. For cells treated with nanogold, the mean intensities of the fields with cells 
(Ii) and without cells (I0,i , background) were calculated. The concentration of 
gold/silver (ci) can be represented as a mean intensity according to the Beer–Lambert 
law:  
 
𝑐𝑖 =
𝐴𝑖
𝜀 𝑑
=
1
𝜀 𝑑
𝑙𝑛
𝐼0,𝑖
𝐼𝑖
       (1) 
𝐶𝑖
𝐶𝑛𝑡
=
𝑙𝑛 (
𝐼0,𝑖
𝐼𝑖
⁄ )
𝑙𝑛 (
𝐼0,𝑛𝑡
𝐼𝑛𝑡
⁄ )
⁄      (2) 
where Ai is the absorbance;  is the extinction coefficient and d is the thickness of the 
sample. For cells not treated with nanogold, cnt, Int, and I0,nt  correspond to the 
concentration of gold/silver, measured as the mean intensities of the fields with and 
without cells, respectively. We assume that the extinction coefficient and thickness are 
the same for all slides, so that the ratio of concentrations can be calculated according 
to equation (2) by knowing the mean intensities.  
 
Tumor targeting in mice 
Athymic female nude mice ranging in age from 4 to 6 weeks and weighing from 15 to 
18 g were obtained from Harlan Laboratories (Indianapolis, IN), 38 mice were used in 
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the study. Mouse tumors were established by subcutaneous injection of HeLa cells 
(10
6
 cells/0.1 ml/flank) in the right flank of each mouse. When tumors reached 5-8 
mm in diameter, intratumoral or tail vein injections of nanogold samples were 
performed. For intratumoral injection, 50 μL of 20 μM nanogold or nanogold-pHLIP 
in sterile PBS (pH7.4) was given at each of three different spots in each tumor. For tail 
vein injection, two consecutive injections of 150 μL of 20 μM nanogold-pHLIP or 
non-functionalized nanogold and nanogold-K-pHLIP as controls were given within 24 
h. Animals were euthanized at 4 or 24 h after the last injection. Necropsy was 
performed immediately after euthanasia. Tumors and major organs were collected for 
further histological analysis and study using inductively coupled plasma mass 
spectroscopy (ICP-MS). Non-injected mice with similar-sized tumors were used as 
negative controls.    
 
All animal studies were conducted according to an approved animal protocol (AN07-
01-015), in compliance with the principles and procedures outlined in the NIH Guide 
for the Care and Use of Animals. 
 
Histological analysis of tumors and organs  
The excised tumors and organs were fixed in 4% formalin in PBS solution (pH 7.4) 
for 24 h at 4°C. Tissues were then rinsed with sterile PBS (pH7.4), blotted dry, and 
placed in 30% sucrose in PBS solution for at least 24 h at 4°C. Samples were mounted 
in HistoPrep
®
 frozen tissue embedding medium (Fisher Scientific; Pittsburgh, PA) and 
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frozen in the quick freezer chamber of a cryostat (Vibratome UltraPro5000, GMI; 
Ramsey, MN) at −80°C. Samples were frozen only one time, to minimize tissue 
damage. When the temperature of mounted frozen samples was equilibrated with the 
working chamber temperature (−12°C), the tissue was sectioned at a thickness of 10–
20 μm. Sections were mounted on microscope slides coated with poly-lysine, dried in 
air, and washed with deionized water. Subsequently, silver enhancement of gold 
nanoparticles was carried out (developing time: 10 min). In some cases, further 
staining with 4′,6-diamidino-2-phenylindole (DAPI) was performed to stain cell 
nuclei. The stained section was covered with a drop of mounting medium (Permount
®
, 
Fisher Scientific; Pittsburgh, PA) and then a cover slide was placed over the medium. 
The slides were examined with an inverted fluorescence microscope (IX71 Olympus).  
 
ICP-MS analysis 
Mouse tissue samples were dissolved in aqua regia, freshly prepared by mixing 
concentrated nitric and hydrochloric acids in a volume ratio of 1:3.  If necessary, 
sonication or heating was used to facilitate the digestion of tissue samples. Then the 
concentrated sample solutions were diluted to 10 mL to give 2% nitric acid and 
analyzed via ICP-MS (Thermo scientific X7 series) against calibration standards IMS 
103 (UltraScientific; N.Kingston, RI).  
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FIGURES 
 
 
 
 
Figure 1. Circular dichroism spectra of gold-pHLIP in buffer pH 8.0 (state I), and 
in the presence of POPC liposomes at pH 8.0 (state II), and pH 4.0 (state III).  
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Figure 2. Cellular uptake of gold-pHLIP and gold nanoparticles. Nanoparticles (2 
μM, 200 μL) were incubated with HeLa-GFP cells at pH7.4 or 6.5. After 1 hour, cells 
were washed, fixed, and stained with silver enhancement solution, resulting in the 
deposition of silver on gold nanoparticles to form micrometer sized particles, which 
were visualized under a light microscope. The images a-g and d-h were taken with 
x10 and x40 objectives, respectively. 
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Figure 3. ICP-MS analysis of the amount of gold in the excised tissues. Either a 
single intratumoral injection of gold-pHLIP or gold nanoparticles (a; 20μM, 50μL) or 
two IV injections of gold-pHLIP, gold-K-pHLIP and gold (b; 20μM, 150μL each) 
were given to mice bearing subcutaneous tumors. Organs were collected at 24 h after 
the last injection. Organ uptakes of gold via intratumoral and IV injections are shown 
in (a) and (b), respectively. The amount of gold per gram of tissue is given in Table 
S1, supporting information. Mean ± SEM values are shown; *p<0.0001 vs respective 
value of tumor uptake of gold targeted by gold-pHLIP. 
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Figure 4.  Accumulation of gold-pHLIP and gold nanoparticles in tumor, kidney, 
and liver. The slices indicated by * were not treated with silver enhancement solution.  
 
Figure 5. Photomicrographs (x10) of gold nanoparticles in tumor, kidney, and 
liver sections after silver staining.  
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Figure 6. Distributions of gold-pHLIP enhanced by silver in tumor, kidney, and 
liver. Slices were visualized under an inverted optical microscope with a x100 
objective.  The nuclei were stained with DAPI (blue color). Bright field (a, d, g) and 
fluorescent (b, e, h) images of the same sections and their overlays (c, f, i) of tumor, 
kidney, and liver slices are presented.  
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SUPPORTING INFORMATION 
 
 Au-pHLIP, 
IT 
n=5 
Au, IT 
n=4 
Au-pHLIP, 
IV 
n=10 
Au-K-
pHLIP, IV 
n=7 
Au, IV 
n=4 
Blood 
Tumor 
Heart 
Lung 
Liver 
Kidney 
Spleen 
Bladder 
Stomach 
Intestine 
Muscle 
Brain 
0.100.25 
8.051.69 
0.490.29 
0.640.49 
1.290.57 
2.140.37 
0.870.55 
0.540.68 
0.020.07 
0.120.04 
0.470.41 
0.020.07 
0.120.06 
0.720.35 
0.050.02 
0.090.04 
0.210.09 
0.940.39 
0.110.05 
0.240.11 
0.050.02 
0.080.04 
0.170.06 
0.190.09 
0.630.04 
1.350.24 
0.620.04 
0.900.14 
19.271.24 
14.760.52 
8.240.93 
1.560.44 
0.500.03 
0.780.11 
0.290.02 
0.080.02 
0.580.09 
0.470.11 
0.390.03 
0.660.10 
23.991.82 
5.350.80 
13.231.91 
1.090.10 
0.300.03 
0.300.03 
0.200.03 
0.060.02 
0.140.05 
0.220.02 
0.070.01 
0.130.01 
0.350.01 
1.350.16 
0.140.04 
0.160.10 
0.090.01 
0.100.02 
0.060.01 
0.010.01 
 
Table 1.  The average amount of gold calculated in micro grams per gram of 
tissue obtained from ICP-MS analysis of the excised tissues after intratumoral 
injection of 15 μg of gold and IV administration of 90 μg of gold. Mean ± SEM values 
are shown, and n is the number of animals used in experiment for each construct. 
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ABSTRACT  
Gold nanoparticles find a wide range of applications in medical sciences. We are 
particularly interested in the use of gold nanoparticles as radio- and thermo-
synthesizers for the enhancement of radiation effects and photo-induced hyperthermia. 
One of the most important aspects of success is the enhancement of gold nanoparticle 
uptake by cancer cells. Therefore, we introduced novel approaches in the synthesis of 
gold nanoparticles coated with tumor-targeting pH (Low) Insertion Peptide (pHLIP
®
) 
and polyethylene glycol (PEG). The presence of pHLIP
®
 peptide in the nanoparticle 
coating enhances the stability of particles and promotes pH-dependent cellular uptake. 
The spherical particles with a metallic core diameter of ~6 nm and a mean 
hydrodymanic diameter of ~43 nm were prepared with citrate as a reducing agent. 
Whe the particles were injected into tumors in mice (21 µg of gold), they were nearly 
homogeneously distributed within tumor masses and did not stain the adjacent muscle 
tissue. One hour after injection, tumors retained up to ~30% of the injected gold. This 
opens the opportunity to use pHLIP
®
 and PEG coated spherical gold nanoparticles for 
the enhancement of radiation therapy. The spiked gold nanoparticles with a metallic 
core diameter of 148 nm and a mean hydrodynamic diameter of ~161 nm were 
prepared using ascorbic acid as a reducing agent in the presence of disk-like bicelles. 
Only the presence of bicelles ensured the appearance of resonance in the near infrared 
region. The illumination of spiked gold nanoparticles by an 805 nm laser led to the 
time- and concentration-dependent increase of temperature. The temperature was 
raised from 26ºC to 40ºC within 5 min. This allows the possibility to use pHLIP
®
 and 
PEG coated spiked gold nanoparticles for photo-induced hyperthermia.   
124 
 
INTRODUCTION 
Gold nanoparticles (ranging in size from 1 to 200 nm) have numerous applications in 
medicine, including the enhancement of x-ray radiation damage to tumor tissues 
1-4
 
and the induction of localized heating in photothermal therapy 
5-7
. The latter is 
achieved when gold nanoparticles are exposed to light and impart heat energy to their 
local environment due to the temporary existence and decay of localized surface 
plasmon polaritons. Whenever gold nanoparticles are used, not only should the 
particles be stable, but they should preferentially target diseased tissue such as a 
cancerous tumor.  
 
Many contemporary therapeutic and imaging approaches to cancer therapy rely on 
tumor-targeting biomarkers such as antibody technologies or vitamin binding 
8-12
. 
Although there are significant successes, the inter- and intra-heterogeneity of tumors, 
their complexity, and their ability to adapt to new conditions often create parts of a 
tumor that may not express enough of the biomarker to be targeted. This results in the 
regrowth of resistant tumors and poor therapeutic outcomes where the average 
improvements in survival are measured in months. At the same time, there is an 
emerging body of evidence indicating that the acidity of the tumor tissue plays a key 
role in determining cancer cell invasiveness and resistance to therapies. Tumors 
exhibit marked heterogeneity due to genetic alterations, which lead to the modification 
of biochemical pathways. These modifications, which result from metabolic 
alterations, lead to a surge in extracellular acidity. Tumor cells adapt to this acid-
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induced toxic environment by stimulating proteins that regulate intracellular 
homeostasis 
13, 14
.  
 
Among pH-targeting agents, the family of pH (Low) Insertion Peptides (pHLIP
®
) find 
a broad range of applications in biomedical sciences. pHLIP
®
 peptides insert across 
cellular membranes in a pH-dependent manner, with one terminus exposed to the 
extracellular space and the other terminus in the cytoplasm 
15-18
. The molecular 
mechanism behind a pHLIP
®
 peptide’s action is based on the protonation of Asp/Glu 
residues, which enhances the peptide’s hydrophobicity and promotes its membrane-
associated folding and insertion as a transmembrane helix 
19, 20
. It was shown that 
pHLIP
®
 peptides have excellent targeting of acidic tumors and allows the specific 
delivery of imaging and therapeutic agents to cancer cells within tumors 
16, 21-23
. The 
number and variety of pHLIP
®
 based nanomedicines continues to grow. For example, 
coating lipid-based, polymeric, and metallic nanoparticles with pHLIP
®
 peptides 
enhances the targeting of acidic tumors and the number particles internalization within 
cancer cells 
24-29
.  
 
We have shown the specific tumor accumulation of gold nanoclusters of 1.4 nm 
diameter conjugated to a pHLIP
®
 peptide 
30
, and an enhancement of radiation effects 
observed for cancer cells treated with these pHLIP
®
 gold nanoclusters 
31
. As well, 
novel photo-induced pHLIP
®
 coated hollow gold nanospheres containing chlorin e6 
were introduced recently 
27, 28
. The nanospheres experience hyperthermia within 5 min 
of laser exposure leading to the release of photosensitizers due to the reduction of 
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electrostatic interaction. While the obtained results are very interesting and promising, 
there are aspects which require improvement and justify further work: i) the coating of 
gold nanoclusters conjugated with pHLIP
®
 peptide should be improved to avoid 
particle aggregation; and ii) a greater amount of gold might be needed in tumors to 
observe significant radiation enhancement effects. Therefore, here we introduce novel 
approaches for the synthesis of pHLIP
®
 and PEG coated spherical and spiked gold 
nanoparticles for the enhancement of radiation treatment and near infrared (NIR) 
thermal therapy.  
 
MATERIALS AND METHODS 
Materials for Synthesis of pHLIP
®
 and PEG Coated Gold Nanoparticles 
Gold III chloride, 5% aqueous solution, was purchased from Salt Lake Metals (Salt 
Lake City, UT). Sodium citrate tribasic, L-ascorbic acid, and urea (98+ %) dehydrate 
were purchased from Sigma-Aldrich Co, LLC (St. Louis, MO). The wild type (WT) 
pHLIP
®
 peptide: 
ACEQNPIYWARYADWLFTTPLLLLDLALLVDADET 
was synthesized and purified by C.S. Bio Co. (Menlo Park, CA), and the concentration 
of the peptide was determined by absorbance at 280 nm (=13,940 M−1 cm−1). m-
polyethylene glycol–SH (mPEG-SH), about 5 kDa in mass, was purchased from 
Creative PEGworks (Chapel Hill, NC). The lipids, 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) and 1,2-diheptanoyl-sn-glycero-3-phosphocholine (DHPC, 
D7PC),  were purchased from Avanti Polar Lipids, Inc (Alabaster, AL). Tris-(2-
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carboxyethyl)phosphine hydrochloride (TCEP) was purchased from Thermo Fisher 
Scientific (Waltham, MA). The procedures for spherical and spiked pHLIP
®
 and PEG 
coated gold nanoparticle synthesis are described in the Results section.  
 
Bicelle Preparation  
Bicelles were prepared by thin-film method: a chloroform solution of DMPC and 
D7PC (DHPC) lipids were dried using a rotary evaporator to produce an even thin 
film, followed by the additional overnight evaporation under a high vacuum to remove 
traces of organic solvents. The lipid layer was re-suspended in 10 mM phosphate 
buffer, pH 6.5, and underwent ten freeze-thaw-vortex cycles using liquid nitrogen and 
a warm bath (40°C).  
 
Purification of Gold Nanoparticles 
To remove large particles (in the case of spherical gold nanoparticles) and excess 
reducing agents, the final solution of particles underwent two forms of filtration. Large 
particles were removed using centrifugation (5 min at 10,000 relative centrifugal force 
(RCF). Excess reducing agents were removed by size-exclusion chromatography using 
Sephadex
TM
 G25 fast spin column.  500 μL of particles was added to 5 mL of 
Sephadex
TM
 G25 gel filtration beads (Sigma-Aldrich Co, LLC) (the beads were 
hydrated in the desired buffer) and centrifuged for 0.5 min increments at roughly 36 
RCF. Amicon
®
 Ultra-0.5, Ultracel-30 membrane, 30 kDa filters (EMD Millipore) 
were used according to manufacterures instructions to concentrate particles for 21 μg 
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injections in vivo. The final spherical nanoparticle solutions were passed through a 0.2 
μm sterile Acrodisk® syringe filter with HT Tuffryn® membrane (Pall Life Sciences) 
for sterilization.  
 
UV-visible Absorption Spectroscopy 
The absorbance of gold nanoparticles was recorded on a Genesys 10S UV-Vis 
Spectrophotometer to establish the wavelength range of resonance.   
 
Particle Size 
The sizes of bicelles and gold nanoparticles in solution were measured by dynamic 
light scattering (DLS) using a Zetasizer Nano ZS (Malvern) instrument and a 
nanoparticle tracking system, Nanosight (NS300, Malvern). Bicelle size histograms 
determined by DLS were fitted with a Gaussian function and the peak size was 
reported. Transmission electron microscopy (TEM) (JEOL 2100) with an accelerating 
voltage of 200 kV at magnifications in the range of 10,000x to 150,000x was used to 
establish the shape, size, and homogeneity of the gold nanoparticles. Samples were 
prepared for TEM by drying 5 μL of the nanoparticle solution on a carbon type-B, 300 
mesh, copper grid (Ted Pella, Inc). 
 
ICP-MS Analysis  
The investigated samples (cells, tumor tissue, or nanoparticles in solution) were 
dissolved in a concentrated solution of aqua regia (1:3 volume ratio of nitric acid and 
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hydrochloric acid) and sonicated. The final solutions were diluted to 2% (wt/vol) nitric 
acid with distilled water and centrifuged to remove organic tissue. The gold content 
was quantified using inductively coupled plasma mass spectrometry (ICP-MS) 
(Thermo scientific X7 series, and Thermo X-Series 2 quadrupole) by using calibration 
standards IMS 103 (UltraScientific).   
 
Heating  
In a PMMA cuvette, 300 μL of solution was illuminated by an 805 nm temperature 
controlled laser diode with 500 mW output (Thorlabs TCLDM9).  The sample was 
irradiated through the cuvette window of 4.5 mm in width and 12.5 mm in depth, 
where 300 μL of the sample reached ~8 mm in height.  The solution temperature was 
measured every minute with an immobilized FLIR E6 thermal imager (FLIR Systems, 
Inc.) from above to avoid obstruction by the cuvette walls. A sample of phosphate-
buffered saline (PBS), pH 7.4, was illuminated and used as a reference. 
 
Cancer Cells 
JC murine mammary-gland adenocarcinoma cells were obtained from the American 
Type Culture Collection (ATCC). The cells were cultured in Roswell Park Memorial 
Institute (RPMI) medium supplemented with 10% fetal bovine serum (FBS) and 10 
μg/mL ciprofloxacin in a humidified atmosphere of 5% CO2 and 95% air at 37°C.   
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Cytotoxicity Assay  
JC cancer cells were seated in a 96-well plate (3,000-3,500 cells per well in 100 μL 
RMPI medium) and incubated overnight. The next day, 100 μL of gold nanoparticles 
in PBS, pH 7.4, supplemented with 10 mM of D-glucose was added to the cells at two 
concentrations and incubated for 48 hours.  Final gold concentrations after the addition 
of particles to cells were 0.025 g/L and 0.0125 g/L. Cell viability was assessed by a 
colorimetric reagent (CellTiter 96 AQueous One Solution Assay, Promega), which was 
added to cells for one hour (without removing treatment solutions), followed by the 
measurement of absorbance at 490 nm by an iMark
TM
 Microplate Absorbance Reader 
(Bio-Rad Laboratories, Inc.). The readings were corrected for the absorbance of gold 
nanoparticles at 490 nm. All samples were prepared in triplicate.  
 
Cellular Uptake of Gold Nanoparticles  
Various amounts of JC cancer cells (from 100,000 to 1 million cells in different 
experiments) were treated in suspension with gold nanoparticles (typically the final 
concentration of gold with cells was 0.06 g/L) for three hours at 37°C in serum-free 
Leibovitz's L-15 medium at pH 6.0 or pH 7.4 (final treatment volume was 500 μL). In 
another experiment, JC cells were pre-treated with gold nanoparticles in serum-free L-
15 medium at pH 7.4 for 20 min, and then media (with different pHs) were added to 
give a total volume of 500 μL and a final solution pH of 7.4 or 6.0-6.2.  After 
treatment, samples were pelleted (5 min at 600 RCF) and washed with PBS, pH 7.4, 
three times. The amount of gold in each pellet was then quantified using ICP-MS.  The 
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amount of gold not taken up by cells was quantified in the supernatant by absorbance 
measurements. Control samples of gold nanoparticles without cells and cells without 
particles were investigated at both neutral and low pH as well.  All samples were 
prepared in triplicate. 
 
Uptake and Distribution of Gold in Tumors  
All animal studies were conducted according to the animal protocol AN07-01-015 
approved by the Institutional Animal Care and Use Committee, University of Rhode 
Island, in compliance with the principles and procedures outlined in the National 
Institutes of Health Guide for the Care and Use of Animals. Female Balb/C mice 
ranging in age from 4 to 6 weeks and weighing from 18 to 22 g were obtained from 
Envigo RMS, Inc; 16 mice were used in the study.  Tumors were established in the 
right flank by subcutaneous injection of JC cancer cells (10
6
 cells in 100 μL). After 
about two weeks, 50 μL of 0.11 g/L gold particles (5.5 µg of gold), or 0.42 g/L gold 
particles (21 µg of gold) in PBS, pH 7.4, supplemented with 10 mM D-glucose were 
injected intra-tumorally. An hour after injection, mice were euthanized and the tumors 
were immediately collected for histological and gold-quantification analysis. The 
amount of gold in each tumor was quantified using ICP-MS. A non-injected mouse 
with a similar-sized tumor was used as a negative control. The distribution of gold 
within the tumor was accessed by white light imaging of the tumor center. 
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Histological Staining and Imaging of Tumor Sections  
Immediately after tumors were collected from the mice, they were frozen in tissue-tek 
OCT compound using liquid nitrogen and stored at -80 °C until sectioned using a 
cryostat at -25°C (Vibratome UltraPro5000, GMI). When the temperature of the 
mounted frozen samples was equilibrated with the working chamber temperature 
(−25°C), the tissue was sectioned at a thickness of 20 μm. Tumor sections were then 
fixed in a 4% formaldehyde solution (Sigma-Aldrich Co.), washed three times with 
deionized water, permeated with 0.3% Triton X-100 (Sigma-Aldrich, Co.) in PBS, pH 
7.4, for one hour, washed two times with deionized water, and stained with HQ 
Silver
TM
 silver enhancement solution (Nanoprobes, Inc) for 15 min followed by a final 
washing. The tumor sections were finally stained with 3 μM of 4′,6-diamidino-2-
phenylindole (DAPI) (Molecular Probes, Thermo Fisher Scientific) for two and a half 
hours to mark the cell nuclei. Adjacent tumor slides were fixed in 4% formaldehyde 
and stained with hematoxylin and eosin (H&E) (Thermo Fisher Scientific and Poly 
Scientific R & D Corp). The stained section was covered with a drop of mounting 
medium (Permount®, Fisher Scientific) and then a cover slide was placed over the 
medium. The slides were examined under an inverted fluorescence microscope (IX71 
Olympus).  
 
RESULTS 
We have synthesized and investigated gold nanoparticles coated with pHLIP and PEG. 
In our study we used WT pHLIP
®
 peptide (4.1 kDa) with a single Cys residue at the 
N-terminus and PEG polymer (about 5 kDa) with a free SH group. The pHLIP
®
 and 
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PEG were used in a mixture with reducing agents, tri-sodium citrate or ascorbic acid 
to prepare spherical or spiked gold nanoparticles, respectively. The pHLIP
®
 peptide 
was dissolved in a solution of 2.7 M urea and mixed (in equal parts) with degassed, 
deionized water containing ten times molar-excess of TCEP, which prevents the 
formation of disulfide bonds. The PEG polymer was dissolved in a degassed, 
deionized water containing ten times molar-excess of TCEP.  
 
Synthesis and Characterization of Spherical pHLIP® and PEG Coated Gold 
Nanoparticles  
To obtain pHLIP
®
 and PEG coated spherical gold nanoparticles, the solution of gold 
III chloride was reduced using tri-sodium citrate mixed with pHLIP
®
 peptide and PEG 
polymer. The solution containing gold III chloride, citrate, pHLIP
®
, and PEG was 
blown with argon (to avoid oxidation of pHLIP
® 
and PEG) and sealed for incubation 
at room temperature. Within 15-20 min a change in color of the solution was observed 
(Supplementary Figure 1S) and particles were left overnight at room temperature to 
ensure the complete reduction of the gold and the coating of nanoparticles by pHLIP
®
 
and PEG. 
 
In the course of this study we varied the amount of citrate, pHLIP
®
, and PEG, then 
monitored changes in absorbance of the nanoparticle solutions for the appearance of a 
resonance peak at 525 nm (Figure 1). The absence of pHLIP
®
 and PEG leads to the 
aggregation and precipitation of particles within a couple of hours after their 
preparation (Figure 1a and Supplementary Figure 1S). The best resonance was 
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observed when gold nanoparticles were coated with both pHLIP
®
 and PEG. The 
amount of sodium citrate was varied from 0.42% to 2.8% wt/vol, where the 
concentration of citrate is reported as a final concentration in the nanoparticle solution 
(Figure 1b). A low amount of citrate (0.42% wt/vol) in solution results in the shift and 
broadening of the resonance peak, as well as the appearance of large particles, which 
was confirmed by the nanoparticle tracking system (data not shown). At the same 
time, particle sizes did not change when the amount of citrate was varied from 0.83% 
wt/vol to 2.8% wt/vol. The best results were obtained when citrate levels were varied 
between 0.83% wt/vol and 1.7% wt/vol. The amount of pHLIP
®
 peptide and PEG 
polymer was altered as well. An increased percentage of pHLIP
®
 and decreased 
percentage of PEG leads to a broadening and shift (by 6-8 nm) of resonance to longer 
wavelengths (Figure 1c). The amounts of 10% pHLIP
®
 and 90% PEG were chosen as 
an optimal configuration. The final selected composition of reagents (0.83% citrate 
and 10% pHLIP-90% PEG) comprised the following molar parts: 0.5 parts of 10 mM 
gold III chloride; 0.075 parts of tri-sodium citrate (10% wt/vol); 0.1125 parts of 0.5 
mM PEG with 5 mM TCEP; 0.0125 parts 0.5 mM pHLIP
®
 peptide with 5 mM TCEP 
and 1.35 M urea, and 0.3 parts of degassed deionized water.   
 
After synthesis, the solution of nanoparticles was purified to remove large particles 
and excess reducing agents. The large particles were removed by centrifugation. The 
excess reducing agents were removed when the nanoparticles were transferred to a 
PBS, pH 7.4, solution using size-exclusion chromatography. 
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Spherical gold nanoparticles coated with pHLIP
®
 and PEG were stable for at least 36 
days at 4°C in PBS, pH 7.4. The stability of gold nanoparticles was assessed at two 
gold concentrations: 0.1 g/L and 0.02 g/L. A high stability profile was obtained for 
both concentrations (Figure 1d). On the other hand, when particles were synthesized 
using a citrate reducing agent containing only PEG, or without both PEG and pHLIP
®
, 
the stability was seriously compromised; particles settled over time forming large 
visible aggregates and the resonance peak was shifted and broadened. Thus, the 
presence of pHLIP
®
 peptide in gold nanoparticle coating is essential to maintain 
colloidal stability over time when using the methods described here.  
 
TEM imaging was employed to analyze the size and shape distributions of gold 
nanoparticles (Figure 1e, f). The nanoparticles were homogeneous and round. Fitting 
the histogram of the particle size distribution by a log-normal function (Figure 1g) 
revealed that the metallic core was about 6.0±2.2 nm in diameter. The mean 
hydrodynamic size (diameter), determined by nanoparticle tracking system, was 
43.0±1.5 nm. 
 
Templated Synthesis and Characterization of pHLIP
®
 and PEG Coated Spiked Gold 
Nanoparticles  
Another approach we explored in the preparation of pHLIP
®
 and PEG coated gold 
nanoparticles was based on use of bicelles as a template. Bicelles are disk-like 
micelles, which consist of long-chain phospholipids, such as 
dimyristoylphosphatidylcholine (DMPC), and short-chain phospholipids, such as 
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dihexanoylphosphatidylcholine (DHPC, D7PC) (Figure 2a). We chose to work with 
D7PC lipids, which have a low critical micelle concentration (CMC). Assuming the 
DMPC and DHPC head groups occupy the same areas, the molar ratio of long-chain to 
short-chain lipids is expressed via q-values, which reflects different aspect ratios of 
disk-like bicelles 
32, 33
:  
 
𝑞 =
[𝐷𝑀𝑃𝐶]
[𝐷𝐻𝑃𝐶]
=
2𝜋𝑅2
𝜋ℎ(𝜋𝑅 + ℎ)
 
 
where R is the radius and h is the height of the bicelle (Figure 2a). The height of the 
bicelles in our study was 4.2 nm and the radius was varied depending on ratio of 
DMPC to DHPC lipids. The diameters of the bicelles of different asymmetry, d(q), 
calculated according to the above equation (without accounting for the DHPC 
capping) are the following:  d(0.2)=4.2 nm; d(0.3)=6.0 nm; d(0.5)=8.6 nm; d(0.75)=12 
nm; and d(1.0)=15 nm. To investigate the integrity of the DMPC-D7PC bicelle 
structures of various aspect ratios, we monitored their change in size at concentrations 
of 1.0, 0.5 and 0.1% wt/vol (Figure 2b). Because we were only concerned with the 
change in size upon dilution, no attempts were made to account for asymmetric 
particle geometries in DLS measurements. A slight increase in size was observed at 
low concentrations (0.1% wt/vol) for bicelles with q-values less than 0.75. On the 
other hand, highly asymmetric bicelles with a q-value equal to 1 lose their structural 
integrity as a result of dilution. Therefore, all other experiments were performed with 
bicelles of q-values of 0.75 and lower.  
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The templated synthesis of pHLIP
®
 and PEG coated spiked gold nanoparticles was 
always initiated shortly after bicelle preparation. We ensured that the addition of the 
gold chloride solution and reducing agents does not lead to the dilution of the bicelle 
solution to lipid concentrations less than 0.1% wt/vol. The following steps were 
performed in the coating of bicelles: i) a solution of gold III chloride was added to the 
solution of bicelles and mixed; ii) next, the reducing agent, ascorbic acid, was added 
and mixed; and iii) upon color change, the solution containing pHLIP
®
 and PEG was 
immediately added to complete the coating process. The appearance of NIR 
absorbance was indicative of the formation of spiked gold nanoparticles. In the 
absence of bicelles, the resonance was shifted to 525 nm (Figure 2c) reflecting the 
formation of solid spherical gold nanoparticles, which was also confirmed by TEM. 
Interestingly, the use of citrate as a reducer instead of ascorbic acid shifts the 
equilibrium towards the formation of solid spherical gold particles rather than 
templated synthesis of gold spiked nanoparticles (data not shown). At the 
concentrations of gold used in this study, the change of bicelle asymmetry (the 
increase of q-values from 0.3 to 0.75) does not affect NIR resonance (Figure 2c). 
Variation in the amount of gold affects the resonance peak just slightly (Figure 2d). 
The normalized absorbance of nanoparticles does not change upon dilution or the 
addition of detergent that disrupts lipid structures, Triton X-100, indicating that the 
nanoparticles have stability and integrity after synthesis (data not shown). The 
presence of pHLIP
®
 and PEG resulted in the formation of particles that were more 
stable in aqueous solutions compared to the particles without coating, which were 
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precipitated shortly after their preparation. The final composition of reagents was the 
following molar parts: 0.05 part of 15 mM of lipids arranged into bicelles (> 0.1% 
wt/vol), 0.15 parts of 5 mM gold III chloride; 0.0225 parts of 250 mM ascorbic acid; 
0.414 parts of 0.5 mM PEG with 5 mM TCEP; 0.046 parts 0.5 mM pHLIP
®
 peptide 
with 5 mM TCEP and 1.35 M urea; and 0.3175 parts of degassed, deionized water.  
 
TEM images of filtered pHLIP
®
 and PEG coated gold nanoparticles demonstrated the 
presence of irregular, spiked gold nanoparticles (Figure 2e). The structures were the 
same for bicelles with different q-values. Conversely, spiked structures were not 
observed in absence of bicelles. The mean size (diameter) of spiked nanoparticles 
established by TEM was 148.0±50.0 nm (Figure 2d). The mean hydrodynamic 
diameter, determined by nanoparticle tracking system, was 160.7±29.0 nm. 
 
Interaction of Spherical pHLIP
®
 and PEG Coated Gold Nanoparticles with Cancer 
Cells 
First, we have tested the cytotoxicity of spherical pHLIP
®
 and PEG coated gold 
nanoparticles. JC murine mammary-gland adenocarcinoma cells were treated with 
gold nanoparticles (0.025 and 0.0125 g/L of gold) for 48 hours. The results indicate 
that gold nanoparticles do not exhibit any cellular toxicity.  
 
Next, we evaluated the pH-dependent cellular uptake of spherical pHLIP
®
 and PEG 
coated gold nanoparticles. The experiment was performed several times in different 
ways, such that the treatment of cells with gold nanoparticles was done at neutral and 
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low pH, or the pre-treatment of cells with gold nanoparticles was done at neutral pH 
followed by the lowering of pH with media. All obtained data indicate that the uptake 
of spherical pHLIP
®
 and PEG coated gold nanoparticles by JC cancer cells at pH 6.0-
6.2 was about 3 times higher than the uptake at neutral pH. The results confirm pH-
dependent cellular uptake of gold nanoparticles coated with pHLIP
®
 and PEG. 
 
Distribution of pHLIP
®
 and PEG Coated Gold Nanoparticles within Tumors 
JC cancer cells were inoculated into the right flank of mice by subcutaneous injection. 
Spherical pHLIP
®
 and PEG coated gold nanoparticles were administered as a single 
intra-tumoral injection at quantities of 5.5 and 21 μg gold. One hour after injection, 
animals were sacrificed so that tumors could be collected and processed to establish 
the amount of gold within and the distribution of particles throughout a tumor. Among 
all of the mice, there were animals with different tumor weights that were separated 
into 3 groups: 0.1, 0.3, and 0.4 g. The percentage of injected dose accumulated within 
the tumors increased with the increase of tumor weight: 16.2% for 0.1 g tumor; 18.0% 
for 0.3 g, and 29.1% for 0.4 g of tumor (Supplementary Figure 2S). The mean tumor 
uptake of gold (calculated for 8 animals) was 6.8 μg of gold per gram of tumor (with a 
standard error of 1.6) when a total of 5.5 μg of gold was injected. The mean tumor 
uptake of gold (calculated for 6 animals) was 24.5 μg/g (with standard error of 8.5) 
when 21 μg of gold was injected. The highest accumulation of gold 47 μg/g was 
found in the smallest tumors (85.0±2.3 mg) injected with 21 μg of gold. 
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Also, we investigated the distribution of gold within a tumor mass. White light images 
were taken from the center of the tumor mass (Figure 3a). Then, the frozen tumor 
samples were sectioned and stained with hematoxylin and eosin (H&E) (Figure 3b). 
The gold was distributed nearly homogeneously within the tumor mass except the 
right edge of the tumor and there was no gold accumulation in the surrounding muscle. 
Muscle tissue adjacent to tumor is indicated by arrows on Figure 3a and 3b, and a 
magnified image of the border of the section containing both cancer cells and muscle 
is shown on Figure 3c. Adjacent sections were treated with Triton to permeabilize 
cellular membranes and stained with silver enhancement solution and DAPI. The 
representative images of gold enhanced by silver and stained nucleus are shown on 
Figure 3d-f.  
 
Heating of pHLIP
®
 and PEG Coated Spiked Gold Nanoparticles  
Three concentrations of pHLIP
®
 and PEG coated spiked gold nanoparticles were 
illuminated in solution by an 805 nm laser diode with 500 mW output. The laser 
radiant exposure was ~400 J/cm
2
. For particles at a concentration of 0.06 g/L gold, a 
temperature increase of 14 degree units (from 26ºC to 40ºC) was observed within 5 
minutes (Figure 4), which is ~18 J imparted to water or ~12 % energy converted to 
heat. More concentrated particles showed greater temperature changes at all time 
points compared to less concentrated particles. 
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DISCUSSION 
The motivation for our work was based on a desire to introduce pHLIP
®
 and PEG 
coated gold nanoparticles. We developed methods for the preparation of pHLIP
®
 and 
PEG coated spherical gold nanoparticles that might find application in radiation 
therapy as enhancement agents, as well as pHLIP
®
 and PEG coated spiked gold 
nanoparticles for NIR thermal therapy. In both cases, pHLIP
®
 peptide and PEG 
polymer were used as components of the reducing solution (sodium citrate reducer in 
the case of spherical nanoparticles and ascorbic acid in the case of spiked 
nanoparticles). The optimal combination of pHLIP
®
 and PEG was selected to be 10% 
and 90%, respectively. A decreased percentage of pHLIP
®
 in the nanoparticle coating 
might lead to the reduction of particle stability (resulting from the reduction of the 
overall negative charge due to the presence of pHLIP
®
 peptide on particle surfaces) 
and the loss of pH-dependent properties. An increase in the percentage of pHLIP
®
 
peptide might be advantageous; but it comes with an increased cost of nanoparticle 
production. Previously, we investigated and showed the utility of liposomes coated 
with different ratios of pHLIP
®
 and PEG 
24, 29
.  As well, employing a pHLIP
®
 PEG 
conjugate instead of directly coating the surface with pHLIP could possibly further 
optimization. Spherical gold nanoparticles coated with pHLIP
®
 and PEG exhibited 
high stability in solution over a one month time period, opposed to the particles with 
no coating or just PEG coating. The size of the metallic core of the particles was in the 
range of 4 to 8 nm in diameter and the hydrodynamic size (diameter) of coated 
particles was in the range of 38 to 48 nm. The nanoparticles showed pH-dependent 
uptake by cancer cells with no signs of cytotoxicity. We performed intra-tumoral 
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injections of spherical gold nanoparticle solutions and investigated gold uptake and 
distribution within tumors at one hour after injection. We focused on intratumoral 
injections because it does not seem like there is any clinical utility to perform a 
systemic administration of particles, since radiation therapy will be delivered locally 
and the location of the tumor would be known from prior imaging. Also, there is a 
requirement to have as much gold as possible within a tumor (which could be 
achieved only by local administration of the particles) to induce radiation 
enhancement effects. To have radiation delivered within a one hour time frame of 
particle administration is expected to be in line with clinical practice. Our results 
indicate that gold nanoparticles (21 µg of injected gold) were distributed within the 
tumor mass very well and with an overall uptake of 24.5 µg of gold per gram of tumor 
mass, reaching values of 47 µg/g in tumors with masses of 1 gram and less. This is a 
higher uptake compared to that of pHLIP
®
 gold nanoclusters 
30
. We believe that the 
presence of pHLIP
®
 peptide in the coating of gold nanoparticles was crucial. The 
peptide allowed particles to stay within the tumor and promoted the uptake of particles 
by cancer cells at low extracellular pH, as we have shown previously 
30, 31
. On the 
other hand, particles were able to diffuse within a tumor as opposed to the direct 
injection of micron-sized gold particles that hindered tumor coverage by staying only 
at the injection site 
3
. Also, we would like to outline that the systemic administration 
of nanoparticles or antibodies conjugated with gold nanoparticles results in the 
staining of only peripheral tumor regions with limited penetration inside the tumor 
mass 
34
. We did not observe accumulation of gold within muscle tissue adjacent to the 
tumors. The amount of injected gold in our study was much less than the amount of 
143 
 
gold used in previous radiation therapy studies on mice (see review and references 
within it 
35
). However, we believe that the targeting of gold nanoparticles directed by 
pHLIP
®
 peptide  to the vital cellular structures such as plasma and nuclear membranes  
(as was shown previously 
31
) could lead to the enhancement of radiation effects even 
at lower gold concentrations.  
 
The synthesis of spiked gold nanoparticles was performed using phospholipid disk-
like bicelles as a template to create nanoparticles with resonance around 800 nm for 
NIR laser thermotherapy. Previously, platinum nanowheels were synthesized by the 
reduction of aqueous platinum with ascorbic acid in the presence of bicelles 
36, 37
. As 
well, other phospholipid structures like spherical liposomes were used as a template 
for gold deposition to create biodegradable plasmon resonant nanoshells, which were 
implemented in the laser-induced release of encapsulated molecules 
38-40
. Another 
approach was based on the assembly of liposomes and micelles, called metallosomes, 
by using lipids conjugated to gold nanoclusters 
41
. Bicelles represent a class of model 
membranes for nuclear magnetic resonance (NMR) structural studies of membrane 
biomolecules 
33, 42-44
, but they have found additional applications in biomedical 
sciences as well 
45-47
. Bicelles are discoidal phospholipid nanostructures at high lipid 
concentrations composed of long- and short-chain lipids or lipid-detergent mixtures. 
At higher lipid-to-detergent q-values (lipid-to-detergent molar ratios) bicelle edges are 
stabilized by the detergent, forming disk-like structures. The limitation in working 
with bicelles is typically the high CMC of lipids and detergents, which restricts the 
degree of bicelle dilution without the lipid phase transforming to vesicles. For 
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example, the CMC of the widely used dihexanoylphosphatidylcholine (D6PC) lipids is 
14 mM. Thus, when the best characterized system of DMPC−D6PC bicelles are 
diluted below CMC, they are expected to be converted into a mixture of free D6PC 
lipids and DMPC lipid bilayer liposomes. The D7PC lipids have a 10 times lower 
CMC (1.4 mM), and it was shown that DMPC−D7PC mixtures retain bicelle 
properties at concentrations even as low as 0.1% wt/vol 
48
. Therefore, we selected the 
DMPC-D7PC lipid system and ensured that the addition of aqueous gold and reducing 
solutions does not lead to the dilution of lipids below 0.1% wt/vol. The presence of 
bicelles induced the formation of spiked gold nanoparticles with plasmon resonance in 
the NIR range. The absence of bicelles leads to the formation of spherical gold 
nanoparticles with absorbance at 525 nm. The size of gold spiked nanoparticles 
established by TEM imaging and nanoparticle tracking system was in the range of 100 
to 170 nm and 130 to 200 nm, respectively. The heating of pHLIP
®
 and PEG coated 
spiked gold nanoparticles in solution by an 805 nm laser diode led to the increase of 
solution temperature by 14 degrees within 5 min. The temperature increase was 
concentration dependent. Our next step would be an evaluation of the effectiveness of 
pHLIP
®
 and PEG coated spiked gold nanoparticles in combination with NIR laser 
treatment for photo-induced hyperthermia. Our goal is to employ lower power NIR 
laser radiation systems, which is currently available for indocyanine green (ICG) 
imaging in clinical endoscopy and laparoscopy (see table 4 for the description of ICG 
clinical imaging systems in the review article 
49
).  
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FIGURES 
 
Figure 1. Characterization of Spherical Gold Nanoparticles. The absorbance 
spectra of spherical gold nanoparticle solutions synthesized a) in absence and presence 
of pHLIP
®
 peptide and/or PEG polymer; b) with various amounts of sodium citrate, 
where the percentage of citrate is reported as the final wt/vol concentration (10% 
pHLIP
®
 and 90% PEG); c) with various amounts of pHLIP
®
 and PEG (1.7% wt/vol 
citrate). d) White light images of particles at the beginning and end of stability studies. 
The representative TEM images of pHLIP
®
 and PEG coated spherical gold 
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nanoparticles obtained at e) 20,000x and f) 40,000x magnifications, and g) the 
corresponding histogram of particle sizes.  
 
 
Figure 2. Characterization of Spiked Gold Nanoparticles. a) The disk-like shape of 
a bicelle with height, h, and radius, R, composed of DMPC and D7PC lipids. b) Size 
dependence of bicelles, established by DLS, on their q-value (which is the ratio of 
long- to short-chain lipids that reflect the asymmetry of a bicelle).  c) The absorbance 
spectra of gold nanoparticles obtained by gold reduced by ascorbic acid, pHLIP
®
, and 
PEG in the absence and presence of bicelles of different asymmetry. d) The 
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absorbance spectra of gold nanoparticles obtained by gold reduced by ascorbic acid, 
pHLIP
®
 and PEG in presence of bicelles of q=0.75, where an increasing amount of 
gold was used and the ratios represent different lipid:gold molar amounts. e) The 
representative TEM image of pHLIP
®
 and PEG coated spiked gold nanoparticles 
obtained at 12,000x magnification, and f) the corresponding histogram of particle 
sizes.  
 
 Figure 3. Tumor Imaging of Spherical Gold Nanoparticle Uptake. a) The white 
light image of a tumor center showing gold distribution (after a 21 μg of intra-tumoral 
injection of pHLIP
®
 and PEG coated spherical gold nanoparticles); b) a section from 
tumor center stained with H&E; and c) the magnified image of the tumor section 
outlined by a square in panel b, which shows tumor (T) and muscle (M). The arrows 
on panels a and b indicate muscle tissue. d) The bright field image of a tumor section 
stained with silver enhancement solution, e) the fluorescent image of the same tumor 
section stained with DAPI to visualize cell nuclei, and f) an overlay of the bright filed 
and fluorescent images.   
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Figure 4. Heating of Spiked Gold Nanoparticles. The change in temperature over 
time measured in solutions containing pHLIP
®
 and PEG coated spiked gold 
nanoparticles of different concentration irradiated by an 805 nm laser.   
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SUPPLEMENTARY MATERIALS 
 
Figure S1. Reduction Time Points of Spherical Gold Nanoparticle Synthesis.  The 
time progression of gold reduction by a solution of citric acid (1.7% wt/vol) to induce 
the formation of gold particles. GNP1 is a sample without pHLIP
®
 and PEG; GNP2 is 
a sample containing pHLIP
®
 but no PEG; GNP3 is a sample containing PEG but no 
pHLIP
®
; and GNP4 is a sample containing both pHLIP
®
 and PEG in the reducing 
solution.   
 
Figure S2. Tumor Uptake of Spherical Gold Nanoparticles Differentiated by 
Tumor Mass. The percentage of injected dose of gold accumulated within tumors of 
different masses. 
